 Form/Template 90702637 Rev/Ver AH  
Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Page 1 of 63 
  
 
 
 
Postmarket Study PS130044  
Uphold LITE Study 
 
 
 
CLINICAL PROTOCOL 
 
U8090 
A Prospective, Non- Randomized, Parallel Cohort, Multi -center Study of Uphold LITE vs. 
Native Tissue for the Treatment of Women with Anterior/Api[INVESTIGATOR_423501]. The protocol should be 
held confidential and maintained in a secure location. 
Do not copy or distribute without written permission from [LOCATION_011] Scientific Corporation.  
  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 1 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page [ADDRESS_534886] Manager  
[LOCATION_011] Scientific Corporation â€“  Urology and Pelvic Health Division  
[ADDRESS_534887]  
Minnetonka, MN [ZIP_CODE]  
Tel: 952 -930-6428  
[EMAIL_8098]  
Coordinating  
Principal Investigator  [CONTACT_19767] L. Noblett, MD  
UC Riverside School of Medicine  
UCOP PATH Building  
[ZIP_CODE] Meridian Pkwy 
Riverside, CA  [ZIP_CODE]  
Tel: 951 -486-4548  
[EMAIL_8099]  
 
 
Original Release: 18 January 2013  
Current Version: 28 February  2018  
 
Revision History  
Revision 
Number  Release  
Date  Template 
Number and 
Version  Section  Change  Reason for Change  
01/AA  12 April 
2013 90702637 
Rev/Ver AC  8. Subject Selection  Updated inclusion/ 
exclusion criteria   To align with the 
AUGS PFD Registry  
20. Safety Reporting  Added pelvic floor 
related events as part 
of reportable safety 
events  To align with the 
AUGS PFD Registry  
4. Device Description  Updated study device 
information  To reflect newer 
version of device  
9. Subject 
Accountability  Updated study 
timeline  Due to this protocol 
amendment and the 
AUGS PFD Registry 
Database Go -Live 
projected date  
11. Statistical 
Considerations  Updated statistical 
sections  Due to the 
development of new 
SAP 
02/AB  03 July 2013  90702637 
Rev/Ver AC  Various  Updated PS number 
throughout document   Updated PS number 
required per FDA  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 2 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 3 of 63 
  Revision History  
Revision 
Number  Release  
Date  Template 
Number and 
Version  Section  Change  Reason for Change  
03/AC  24 October 
2014 90702637 
Rev/Ver AD 7. Design  Clarify anterior 
colporrhaphy language  To align with standard 
of care  
8. Subject Selection  Updated inclusion/ 
exclusion criteria   To clarify POP -Q 
score and remove 
hysterectomy 
requirement to allow 
for both vaginal vault 
suspensions & 
hysteropexies  
7. Design  Physician training 
requirement  To allow physicians to 
verify expertise and 
training  through prior 
use of Uphold & 
Uphold LITE devices  
7. Design  Updated number of 
study sites  To allow for a larger 
number of 
participating sites  
8. Subject Selection  Remove English -
speaking requirement To allow enrollment of 
non-English speaking 
subjects  
9. Subject 
Accountability  Updated study 
timeline  To align with current 
enrollment cadence  
10. Study Methods  Updated Data 
Collection 
Schedules/Tables  To align with content 
of protocol  
11. Statistical 
Considerations  Updated ITT 
definition  To clarify definition  
20. Safety Reporting  Updated Safety 
Reporting  To align with data 
collection in the 
AUGS PFD Registry  
04/AD  21 December 
2015 90702637 
Rev/Ver AF  10. Study Methods  Administrative  To clarify the baseline 
assessment of urine 
pregnancy test  
18. Potential Risks and 
Benefits  Updated Anticipated 
Adverse Events  To align with the 
device labeling  
05/AF  03 February 
2016  90702637 
Rev/Ver AF  9. Subject 
Accountability  Updated study 
timeline  To reflect new 
milestone dates  
06/AG  25 September 
2017 * 90702637 
Rev/Ver AH Contact [CONTACT_423536] â€œsponsorâ€ to 
[LOCATION_011] Scientific  To clarify who the 
sponsor is  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 3 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 4 of 63 
  Revision History  
Revision 
Number  Release  
Date  Template 
Number and 
Version  Section  Change  Reason for Change  
2. Protocol Synopsis -
Study Duration;  
8.1. Scale and Duration;  
11.4.7. Months 6, 12, 
18, 24, 36 Visits  Deleted â€œper protocolâ€ 
from subject 
description  To clarify the study 
population  
2. Protocol Synopsis -
Planned Number of 
Subjects;  
8.1. Scale and Duration  Deleted reference to 
mesh subjects  To clarify which 
subjects will be shared 
from the PFD Registry  
10.1. Point of 
Enrollment Revised study 
population description  To clarify the Intent -
to-Treat and Per 
Protocol groups  
10.1. Point of 
Enrollment Revised study timeline 
table  To update actual and 
expected dates for 
study milestones  
10.2. Withdrawal  Added sections on 
voluntary and 
involuntary 
withdrawal, lost to 
follow -up, death and 
documentation  To clarify early 
withdrawal categories  
11.1. Data Collection;  
11.4.5. Follow -Up Added definition of 
missed visit and 
ending 36 Month visit 
window  To clarify missed visit 
definition  
12. Statistical 
Considerations  Various  To align with updated 
Statistical Analysis 
Plan 
11.3. Informed 
Consent;  
13.2. Data Retention;  
17.1. Statement of 
Compliance  Replaced reference to 
ICH-GCP with 
ISO14155:2011 To clarify which GCP 
standards were 
adhered to  
19.2.1. Mesh Exposure 
and Erosion Event 
Classification  Replaced physical 
exam with pelvic exam  To clarify exam type  
20. Informed Consent  Added [LOCATION_011] 
Scientific or CRO for 
informed consent  
review  To clarify informed 
consent review process  
21. Safety Reporting  Revised section for AE 
definitions and 
reporting timelines  To clarify definitions 
and reporting timelines  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 4 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 5 of 63 
  Revision History  
Revision 
Number  Release  
Date  Template 
Number and 
Version  Section  Change  Reason for Change  
07/AH 05 January 
2018* 90702637 
Rev/Ver AH 10.2.4. Subject Death;  
11.6. Subject Death;  
11.1. Data Collection;  
21.7. Investigator 
Reporting 
Requirements  Revised collection of 
death information to 
include all events    To align with FDA 
Guidance on [ADDRESS_534888] - 
Market Surveillance 
[IP_ADDRESS]. Statistical 
Methods ; 
12.2.1. Analysis Sets  
 Added â€œper protocolâ€ 
group to primary 
safety endpoint 
evaluation  To clarify evaluation 
of the primary safety 
endpoint  
[IP_ADDRESS]. Subjects with 
surgical intervention for 
recurrence or 
complications  Added section  To specify the analysis 
of adverse events by 
[CONTACT_423537] -surgery  
08/AI 28 February 
2018 90702637 
Rev/Ver AH 11.1. Data Collection;  
11.4.5. Follow -Up Increased window for 
follow -up visits to 
occur  To reduce number of 
late visits  
11.4.5. Follow -Up Provide option for 
completion of home or 
phone follow -up visits  To improve collection 
of follow -up visit data  
[IP_ADDRESS]. Statistical 
Methods  Added tippi[INVESTIGATOR_423502]  
12.2.3. Propensity 
Score Methodology  Added definition of 
treatment arms  To clarify  how logistic 
regression will be 
performed  
12.3.8. Interim Analysis  Added details of 
interim analysis of 12 
month outcomes  Requested by [CONTACT_8415]  
* Not released separately to the study sites
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 5 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 6 of 63 
  2. Protocol Synopsis  
Postmarket Study PS130044:  A Prospective, Non -Randomized,  Parallel 
Cohort, Multi -center Study of Uphold LITE vs. Native Tissue for the 
Treatment of Women with Anterior/Api[INVESTIGATOR_423503](s) The purpose of this study is to compare transvaginal mesh repair to 
traditional native tissue re pair in women surgically treated for anterior 
and/or api[INVESTIGATOR_423504].  This study is being conducted in 
partnership with the American Urogynecologic Society (AUGS) under 
the Pelvic Floor Disorders Outcome Registry (PFD Registry).   
Test Device  Transvaginal mesh (Uphold Lightweight Vaginal Support System)  
Control Device  Traditional native repair (sacrospi[INVESTIGATOR_423505]/or colporrhaphy)  
Study Design  Non-randomized, parallel cohort, multi -center study.   
All procedures will be standardized for uniformity.  Physicians will 
have to document a minimum of 10 procedures with either the Uphold 
device (i.e., Uphold or Uphold LITE) or with native tissue repair  prior 
to participation in order to document competency and experience.  
Physician training, specialty, and site procedure location (such as 
private -practice, hospi[INVESTIGATOR_307], academic medical center, etc.) will be 
recorded.  
Concomitant procedures including ante rior and posterior vaginal wall 
repair, hysterectomy and sling placement for stress urinary incontinence 
may be performed, per physician discretion.  Sling placement can 
include a synthetic material; however a concomitant anterior or 
posterior repair cannot include a mesh implant.  An anterior 
colporrhaphy may be required for cystocele repair, if clinically 
necessary.  All concomitant procedures performed will be recorded .  
Subjects who undergo a medi cal intervention (surgical or non -surgical) 
to treat recurrence, persistence of pelvic organ prolapse or a mesh 
complication will be followed to 36 months from the initial study 
procedure.   
Planned 
Number of 
Subjects  Approximately 414 subjects enrolled ( 207 subjects per arm) .  Eligible 
control subjects meeting the study inclusion/exclusion criteria may be 
shared from the PFD Registry.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 6 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 7 of 63 
  Postmarket Study PS130044:  A Prospective, Non -Randomized,  Parallel 
Cohort, Multi -center Study of Uphold LITE vs. Native Tissue for the 
Treatment of Women with Anterior/Api[INVESTIGATOR_423506] / Countries  Up to 40 study centers in the [LOCATION_002] . 
Primary 
Effectiveness 
Endpoint(s)  The primary endpoint of the study is to achieve superiority of mesh over 
native tissue repair at 36 months as compared to baseline.  Success will 
be based on a composite of objective and subjective measures, and 
subjects will be considered a surgical success if each of the three criteria 
is met:   
1. Objective success is achieved by [CONTACT_423538]:  
â€¢ Anterior segment:  Leading edge of anterior prolapse is at or 
above the hymen or POP -Q point Ba â‰¤ 0. 
â€¢ Api[INVESTIGATOR_423507]:  The vaginal apex does not descend more 
than one -half into the vaginal canal (i.e. POP -Q point C <  
-1/2 TVL) for multi- compartment prolapse or POPQ point C 
â‰¤ 0 for single compartment api[INVESTIGATOR_19529] l prolapse.  
2. Subjective success is achieved if the patient denies symptoms of 
vaginal bulging per PFDI -20 question 3, answering â€œnoâ€ or â€œyesâ€ 
but â€œNot at allâ€ bothersome (<2).  
3. No retreatment for POP:  no additional surgical treatment for POP 
in the segment( s) of the vagina treated at the index surgery or no 
pessary use since index surgery (i.e., â€˜treated segmentâ€™ refer to the 
target compartment).  
Primary Safety 
Endpoint(s)  A co -primary endpoint of the study is to achieve non -inferiority of mesh 
to native ti ssue repair for safety by [CONTACT_423539] -related complications between baseline and the 36 
month time point.  Serious injury is defined per 21 CFR 803.3, i.e., life 
threatening, results in permanent impairment of a body function or 
permanent damage to a body structure, or injury or illness that requires 
medical or surgical intervention to preclude impairment of a body 
function or permanent damage to a body structure.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 7 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 8 of 63 
  Postmarket Study PS130044:  A Prospective, Non -Randomized,  Parallel 
Cohort, Multi -center Study of Uphold LITE vs. Native Tissue for the 
Treatment of Women with Anterior/Api[INVESTIGATOR_423508]  1. Incidence of mesh erosion  
2. Incidence of mesh exposure  
3. Incidence of de novo dyspareunia  
4. Improvement in subject specific outcomes at 36 months compared 
to Baseline (pelvic floor symptoms (PFDI -20), QOL (PFIQ -7), 
sexual functioning (PI[INVESTIGATOR_45220] -12), TOMUS pain scale  
5. Assessment of subjectâ€™s level of improvement, measured by [CONTACT_423540] (PGI -I for 
Prolapse)  
6. Absence of re- intervention or re -surgery for recurrence or 
persistence of POP or mesh exposure/erosion  
7. Surgical success based on the following composite outcome:  
a. Subjective success:  patient denies symptoms of vaginal 
bulging per PFDI -20 question 3, answering â€œnoâ€ or â€œyesâ€ but 
â€œNot at allâ€ bothersome (<2)  
b. Anatomic success (in the operated compartment):  
â€¢ Anterior Segment:  No anterior prolapse at or 
beyond the hymen or POP -Q point Ba<0 
â€¢ Api[INVESTIGATOR_423509]:   The vaginal apex does not 
descend more than one -half into the vaginal canal 
(i.e. POP -Q point C < 1/2 TVL) for multi -
compartment prolapse or POPQ point C Ë‚ 0 for 
single compartment api[INVESTIGATOR_385303]  
c. No retreatment for POP:  No additional surgical treatment for 
POP in the segment(s) of the vagina treated at the index 
surgery or no pessary use since index surgery  
8. Device or procedure -related incidence of the following:  pelvic 
pain, infection, vaginal shorte ning, atypi[INVESTIGATOR_67260], 
neuromuscular problems, vaginal scarring, de novo vaginal 
bleeding, fistula formation and/or de novo voiding dysfunction 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 8 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 9 of 63 
  Postmarket Study PS130044:  A Prospective, Non -Randomized,  Parallel 
Cohort, Multi -center Study of Uphold LITE vs. Native Tissue for the 
Treatment of Women with Anterior/Api[INVESTIGATOR_423510] a prospective, non -randomized, parallel cohort, multi -
center study.  Approximately 414 subjects will be enrolled and will 
either receive transvaginal mesh (treatment) or a native tissue repair 
(control) procedure.  Study centers will either p articipate to enroll only 
mesh subjects or only native tissue subjects to reduce bias; or a 
combination of mesh and native tissue subjects depending on subject 
population and per Sponsor discretion.   
Follow -up 
Schedule  Study follow -up duration is for 3 y ears from primary study procedure:  
â€¢ Screening/Enrollment Visit  
â€¢ Pre-procedure/Baseline Visit  
â€¢ Procedure and Discharge  
â€¢ Month 2 Visit  
â€¢ Month 6 Visit  
â€¢ Month 12 Visit  
â€¢ Month 18 Visit  
â€¢ Month 24 Visit  
â€¢ Month 36 Visit (Primary Endpoint and End of Study)  
Study Duration  Approximately 3 years (36 months) from last subject enrolled.  
Key Inclusion 
Criteria  1. Subject is female  
2. Subject is â‰¥[ADDRESS_534889] has pelvic organ prolapse with the leading edge at or 
beyond the hymen.   At or beyond the hymen is defined as POP -Q 
scores of Ba â‰¥ 0 (for prolapse of the anterior compartment alone) or 
C â‰¥ 0 (for prolapse of the api[INVESTIGATOR_423511]) or C â‰¥ - 1/2 
TVL and Ba â‰¥ 0 (for a multi -compartment prolapse that includes 
the an terior and api[INVESTIGATOR_423512])  
4. Subject reports of a  bothersome bulge they can see or feel per 
PFDI -20, question 3 response of 2 or higher (i.e. responses of 
â€œsomewhatâ€, â€œmoderatelyâ€ or â€œquite a bitâ€)  
5. Subject or subjectâ€™s legally authorized representative must be 
willing to provide written informed consent  
6. Subject is willing and able to comply with the follow -up regimen  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 9 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 10 of 63 
  Postmarket Study PS130044:  A Prospective, Non -Randomized,  Parallel 
Cohort, Multi -center Study of Uphold LITE vs. Native Tissue for the 
Treatment of Women with Anterior/Api[INVESTIGATOR_423513]  1. Subject is pregnant or intends to b ecome pregnant during the study  
2. Subject has an active or chronic systemic infection including any 
gynecologic infection, untreated urinary tract inf ection (UTI) or 
tissue necrosis  
3. Subject has history of pelvic organ cancer (e.g. uterine, ovarian, 
bladder, colo- rectal or cervical)  
4. Subject has had prior or is currently undergoing radiation, laser 
therapy, or chemotherapy in the pelvic area  
5. Subject has taken systemic steroids (within the last month) or 
immunosuppressive or immunomodulatory treat ment (within the 
last 3 months)  
6. Subject has systemic connective tissue disease (e.g. scleroderma, 
systemic lupus erythematosus (SLE), Marfans syn drome, Ehlers 
Danlos, collagenosis, polymyositis, polymyalgia rheumatica)  
7. Subject has a known neurologic or medical condition affecting 
bladder function (e.g. multiple sclerosis, spi[INVESTIGATOR_1828], or 
stroke wi th residual neurologic deficit)  
8. Subject is se eking obliterative vaginal surgery as treatment for 
pelvi c organ prolapse (colpocleisis)  
9. Subject has a previous prolapse repair with  mesh in the target 
compartment  
10. Subject is planning to undergo a concomitant repair with use of 
mesh in the non- target compa rtment 
11. Subject is not able to conform to the modified dorsal lithotomy 
position  
12. Subject has chronic systemic pain that includes the pelvic area or 
chronic foca l pain that includes the pelvis  
13. Subject has uncontrolled diabetes mellitus (DM)  
14. Subject is curren tly participating in or plans to participate in another 
device or drug study during this  study  
15. Subject has a known hypersensitivity to polypropylene mesh 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 10 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 11 of 63 
  Postmarket Study PS130044:  A Prospective, Non -Randomized,  Parallel 
Cohort, Multi -center Study of Uphold LITE vs. Native Tissue for the 
Treatment of Women with Anterior/Api[INVESTIGATOR_423514] -inferior in safety.  Superiority testing for 
effectiveness will be performed for the primary hypothesis.    
Statistical testing will be performed to dete rmine if composite endpoint 
of anatomic and symptomatic success rate in transvaginal mesh repair 
(treatment) group will be superior to traditional native tissue repair 
(control) group.  The null hypothesis is that the success rate in treatment 
group is les s than or equal to the success rate in control group:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¤ 0   
The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘> 0     
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ is the success rate in the treatment group 
and control group respectively.  The rejection of null hypothesis 
indicates the superiority of the treatment group over the control group.  
Statistical testing will be performed to determine if the overall 
complicati on rate (i.e. serious adverse device effects and serious 
procedure -related adverse events) of treatment group is non- inferior to 
that of the control group. The null hypothesis is that the overall 
complication rate in treatment group is greater than or equa l to the rate 
in control group plus margin:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¥âˆ†   
The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  <âˆ†   
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ are the overall complication rate in 
treatment group and control group respectively, and âˆ† >[ADDRESS_534890] 
Method  All statistical analyses will be performed by [CONTACT_423541].  All analyses will be done using SAS (version 
8.0 or higher) statistical software.  Subject summary tables and data 
listings will be provided for the data collected.   
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 11 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 12 of 63 
  Postmarket Study PS130044:  A Prospective, Non -Randomized,  Parallel 
Cohort, Multi -center Study of Uphold LITE vs. Native Tissue for the 
Treatment of Women with Anterior/Api[INVESTIGATOR_423515] a superiority assumption 
with a binary primary outcome. Success, based on a composite endpoint 
of anatomic and symptomatic success at 36 month is assumed to be 
70.0% for the native tissue arm and 85.0% for transvaginal mesh arm.17-
21 With 2- sided type I error of 0.05 and type II error of 0.1 (power 
90%), 316 subjects (158 subjects per arm) are needed to detect 15% 
difference of transvaginal mesh to native tissue repair.  
To assess for safety, the overall complication rate (i.e. serious adver se 
device effects and serious procedure- related adverse events) is 
anticipated to be approximately 14%.22 With type I error of 0.05 and 
type II error of 0.20 (power 80%), 298 subjects (149 subjects per arm) 
are needed to detect non -inferiority with a margin of 10%.    
The rate of device or procedure -related AE de novo dyspareunia is 
anticipated to be approxima tely 9%.24 With type I error of 0.05 and type 
II error of 0.20 (power 80%), 326 subjects (163 subjects per arm) are 
needed to detect non -inferiority with a margin of 7.9%.   
The device or procedure -related AE incidence (pelvic pain, infection, 
vaginal shor tening, atypi[INVESTIGATOR_67260], neuromuscular problems, 
vaginal scarring, de novo vaginal bleeding, fistula formation and/or de 
novo voiding dysfunction) is anticipated to be approximately 12%.22 
With type I error of 0.05 and type II error of 0.20 (pow er 80%), 330 
subjects (165 subjects per arm) are needed to detect non -inferiority with 
a margin of 8.9%.   
To assess for office- based interventions for complications, the rate is 
anticipated to be approximately 2%.22 With type I error of 0.025 and 
type II error of 0.10 (power 90%), 330 subjects (165 subjects per arm) 
are needed to detect non -inferiority with a margin of 5%.    
To assess for surgical intervention for complications, the rate is 
anticipated to be approximately 1%.22 With type I error of 0.025 a nd 
type II error of 0.10 (power 90%), 260 subjects (130 subjects per arm) 
are needed to detect non -inferiority with a margin of 4%.    
Non-surgical subjects will be enrolled by [CONTACT_423542].  
Assuming a 20%  loss to follow -up rate, a total of 414 subjects (207 per 
study arm) will be enrolled to achieve the primary endpoint of success 
at 36 months.   
 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 12 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page [ADDRESS_534891] Death  ............................................................................................. 26 
10.2.5.  Documentation of Early Termination ........................................................ 26 
11. STUDY METHODS  .............................................................................................................. 26 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 13 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 14 of 63 
  11.1.  Data Collection  ....................................................................................................... 26 
11.2.  Study Candidate Screening  ................................................................................... 29 
11.3.  Informed Consent  .................................................................................................. 29 
11.4.  Study Visit Schedule  .............................................................................................. 29 
11.4.1.  Screening/Enrollment Visit  ....................................................................... 29 
11.4.2.  Pre-Operative/Baseline Visit  ..................................................................... 29 
11.4.3.  Surgery (â‰¤ 3 months from Baseline Visit)  ................................................. 30 
11.4.4.  Discharge  ................................................................................................... 30 
11.4.5.  Follow -Up .................................................................................................. 31 
11.4.6.  Month 2 Visit (Â±4 Weeks)  ......................................................................... 31 
11.4.7.  Months 6, 12, 18, 24, 36 Visits ( -4/+12 weeks)  ........................................ 31 
11.5.  Re-Intervention/Re -Surgery .................................................................................. [ADDRESS_534892] Death .......................................................................................................... 33 
12. STATISTICAL CONSIDERATIONS  ....................................................................................... 33 
12.1.  Endpoints  ................................................................................................................ 33 
12.1.1.  Prim ary Endpoint  ....................................................................................... 33 
[IP_ADDRESS].  Hypotheses  ................................................................................ 33 
[IP_ADDRESS].  Sample Size  ............................................................................... 34 
[IP_ADDRESS].  Statistical Methods  .................................................................... 34 
12.1.2.  Secondary Endpoints  ................................................................................. 35 
[IP_ADDRESS].  Hypotheses  ................................................................................ 36 
[IP_ADDRESS].  Sample Size  ............................................................................... 36 
[IP_ADDRESS].  Statistical Methods  .................................................................... 37 
12.2.  General Statistical Methods .................................................................................. 38 
12.2.1.  Analysis Sets .............................................................................................. 38 
12.2.2.  Control of Systematic Error/Bias  ............................................................... 38 
12.2.3.  Propensity Score Methodology .................................................................. 38 
12.3.  Data Analyses  ......................................................................................................... 39 
12.3.1.  Rate of Office- Based Intervention for Recurrence  .................................... 40 
12.3.2.  Rate of Surgical Intervention for Recurrence  ............................................ 40 
12.3.3.  Rate of Office- Based Intervention for Complications  ............................... 40 
12.3.4.  Rate of Surgical Intervention for Complications  ....................................... 41 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 14 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 15 of 63 
  12.3.5.  Sub-Analysis for Sling Repair and Interventions for Recurrence  ............. 41 
[IP_ADDRESS].  Subjects with only POP repair and those with sling and 
prolapse repair  ........................................................................... 41 
[IP_ADDRESS].  Subjects with office -based intervention for recurrence  ............ 42 
[IP_ADDRESS].  Subjects with surgical intervention for recurrence  ................... 42 
[IP_ADDRESS].  Subjects with surgical intervention for recurrence or 
complications  ............................................................................ 42 
12.3.6.  Additional Data Analyses .......................................................................... 42 
12.3.7.  Sub-Analysis for Interventions for Complications  .................................... 43 
12.3.8.  Interim Analysis  ......................................................................................... 43 
[IP_ADDRESS].  Hypotheses  ................................................................................ 43 
[IP_ADDRESS].  Statistical Methods  .................................................................... 44 
12.3.9.  Justification of Pooling  .............................................................................. 44 
12.3.10.  Multivariable Analyses  .............................................................................. 44 
13. DATA MANAGEMENT  ........................................................................................................ 45 
13.1.  Data Collection, Processing, and Review  ............................................................. 45 
13.2.  Data Retention  ........................................................................................................ 45 
14. AMENDMENTS  ................................................................................................................... 46 
15. DEVIATIONS  ...................................................................................................................... 46 
16. DEVICE /EQUIPMENT ACCOUNTABILITY  .......................................................................... [ADDRESS_534893]/ Ethics Committee  ................................................... 48 
17.4.  Sponsor Responsibilities  ........................................................................................ 49 
17.5.  Insurance ................................................................................................................. 49 
18. MONITORING  ..................................................................................................................... 49 
19. POTENTIAL RISKS AND BENEFITS  .................................................................................... 50 
19.1.  General  .................................................................................................................... 50 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 15 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 16 of 63 
  19.2.  Anticipated Adverse Events  .................................................................................. 50 
19.2.1.  Mesh Exposure and Erosion Event Classification  ..................................... 51 
19.3.  Risks Associated with Particip ation in the Clinical Study  ................................. 51 
19.4.  Risk Minimization Actions  .................................................................................... 52 
19.5.  Anticipated Benefits  ............................................................................................... 52 
19.6.  Risk to Benefit Rationale  ....................................................................................... 52 
20. INFORMED CONSENT  ......................................................................................................... 52 
21. SAFETY REPORTING  .......................................................................................................... 54 
21.1.  Reportable Events by [CONTACT_5716]  ......................... 54 
21.2.  Definitions and Classification  ............................................................................... 54 
21.3.  Relationship to Study Device (Mesh Cohort Only)  ............................................. 55 
21.4.  Relationship to Study Delivery Device (Mesh Cohort Only)  ............................. 55 
21.5.  Relationship to Study Procedure  .......................................................................... 56 
21.6.  Relationship to Pelvic Floor  .................................................................................. 56 
21.7.  Investigator Reporting Requirements .................................................................. 57 
21.8.  [LOCATION_011] Scientific Device Deficiencies .................................................................... 59 
21.9.  Reporting to Regulatory Authorities / IRBs / ECs / Investigators  .................... 59 
22. COMMITTEES  .................................................................................................................... 59 
22.1.  Safety M onitoring Process  ..................................................................................... 59 
23. SUSPENSION OR TERMINATION  ......................................................................................... 59 
23.1.  Premature Termination of the Study  ................................................................... 59 
23.1.1.  Criteria for Premature Termination of the Study  ....................................... 60 
23.2.  Termination of Study Participation by [CONTACT_71636]/ EC Approval  .................................................................................................. [ADDRESS_534894] Follow -up ................................. 60 
23.4.  Criteria for Suspending/Terminating a Study Center  ........................................ 60 
24. PUBLICATION POLICY  ....................................................................................................... 61 
25. REFERENCES  ..................................................................................................................... 62 
  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 16 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 17 of 63 
  3.1. Table of Tables  
Table 10.1- 1: Study Timeline  ................................................................................................. 25 
Table 11.1- 1: Data Collection Schedule  ................................................................................. 27 
Table 11.1- 2: Data Collection Schedule for Subjects Requiring a Re -Surgery  ...................... 28 
Table 21.2- 1: Adverse Event Definitions  ............................................................................... 54 
Table 21.3- 1: Criteria for Assessing Relationship of Study Device to Adverse Event  .......... 55 
Table 21.4- 1: Criteria for Assessing Relationship of Study Delivery Device to Adverse 
Event  ..........................................................................................................56  
Table 21.5- 1: Criteria for Assessing Relationship to Study Procedure  .................................. 56 
Table 21.6- 1: Criteria for Assessing Relationship to Pelvic Floor  ......................................... 57 
Table 21.7- 1: Investigator Reporting Requirements  ............................................................... 57 
 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 17 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 18 of 63 
  4. Introduction  
Pelvic organ prolapse (POP) of the anterior and posterior vaginal wall, and vaginal apex, are 
among the most challenging and common aspects of traditional pelvic reconstructive surgery.  
As life expectancy increases, significantly greater numbers of women will present with POP 
and stress urinary incontinence (SUI) requiring surgical intervention.  Women face an 11% 
lifetime risk of requiring major surgery for POP.9   
The main goal of POP surgery is restoration of normal anatomy to achieve proximal vaginal 
suspension, mid- vaginal lateral attachments and distal vaginal fusion to the urogenital fascia 
and perineum.  Women undergoing pelvic reconstructive surgery for POP hope to achieve 
relief  of symptoms, restoration of normal anatomy, maintenance of vaginal capacity for 
sexual function and improvement in the quality of life.  
The difficulties associated with repair of cystocele were cited by [CONTACT_423543] 1909, and 
reinforced nearly a cen tury later by [CONTACT_195719]. (2001) who reported recurrence rates as high 
as 70% in a widely cited randomized controlled study (RCT).11  Clark et al. estimated that up 
to 60% of surgical recurrences occur at the same anatomic site as the original repair, 
highlighting the limitations associated with plicating and/or suspending weakened connective 
tissues to one another.[ADDRESS_534895] well 
established surgical alternative to native tissue plication.   Despi[INVESTIGATOR_040] a risk of mesh 
complications (3% -  13%), vaginal mesh repair is quicker and technically  easier than trans -
abdominal placement using sacral colpopexy.10,2,6,7,8,4,3 
In an update of surgical treatment of POP, McIntyre et al . (2010)  discussed the potential 
benefits of mesh use.  In the treatment of anterior prolapse, studies indicated that pote ntial 
benefits of mesh include increased durability of repair and improved anatomic outcomes.5  In 
one study of 70 subjects using mesh, McIntyre reported three (4.28%) recurrences, mesh 
extrusion in five subjects (7.1%), and 48 (87.3%) subjects reporting c omplete subjective 
satisfaction with their surgery at a follow -up of 18- 36 months. 
Four recent single -arm studies involving use of a mesh device for treatment of prolapse and 
one to two year follow -up documented anatomica l cure rates ranging from 88.5% -94%.6,7,2,10  
Reported vaginal mesh erosion rates for anterior repair ranged from 3.2% -6.5%, with one 
study reporting 13% mesh erosion for posterior repair.[ADDRESS_534896]â€™s rep orted 
>50% reduction in the cystocele recurrence rate, and four of seven reported > 75% reduction 
in anatomic failures.   Crude recurrence rates were reduced, in these studies, from a range of 
28-45% (colporrhaphy) to 7- 21% (mesh).   
 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 18 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 19 of 63 
  Upholdâ„¢ Lightweight Surgical Mesh (Uphold LITE) is an FDA 510(k) cleared mesh 
implant intended for tissue reinforcement and stabilization of fascial structures of the pelvic 
floor in vaginal wall prolapse, where surgical treatment is intended, either as mechanical 
support or br idging material for the fascial defect.  Uphold was designed as a VMR that 
would limit mesh exposures by [CONTACT_423544] a horizontal, inverted crescent vaginal 
incision near the urethrovesical junction.  The amount of mesh is approximately 75% less 
than other kits and api[INVESTIGATOR_423516] (SSLF).  
Use of synthetic mesh grafts in surgical repair of vaginal prolapse has been shown to 
significantly increase success rates and reduce recurrent prolapse.  
5. Device Descript ion 
The Uphold LITE Vaginal Support System is a sterile, single use device for transvaginal 
placement, consisting of one (1) Uphold LITE Synthetic Mesh Assembly and one (1) Capio 
â„¢ SLIM Suture Capturing Device.  The mesh assembly is a light -weight knitted mesh that 
consists of undyed and dyed polypropylene and monofilament fiber (phthalocyanine blue, 
color index number [ZIP_CODE]) with two integrated leg assemblies.  The leg assemblies include a 
dart, lead, dilator, two leader loops and protective sleeve.  The dart at the distal end of the leg 
assembly was designed to be placed into the carrier at the distal end of the Capio SLIM 
Suture Capturing Device.  The leg assembly was designed to facilitate the passage of the 
Uphold LITE Synthetic Mesh Assembly through bodily tissues for placement through 
sacrospi[INVESTIGATOR_11599].   One dilator is striped to differentiate each leg assembly (left/right).  
6. Study Objectives  
The primary objective is to evaluate clinical effectiveness of transvaginal mesh repair against 
traditional native tissue repair in women surgically treated for anterior and/or api[INVESTIGATOR_423517].  Secondary objectives are to evaluate mesh -related complications and subject 
reported outcomes.  
7. Study Endpoints  
7.1. Primary Endpoint s 
The primary endpoint of the study is to achieve superiority of mesh over native tissue repair 
at 36 months as compared to baseline.   
Success will be based on a composite of objective and subjective measures, and subjects will 
be considered a surgical succ ess if each of the three criteria is met:   
1. Objective success is achieved by [CONTACT_423545]:  
â€¢ Anterior segment:  Leading edge of anterior prola pse is at or above the hymen 
or POP -Q point Ba â‰¤ 0.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 19 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 20 of 63 
  â€¢ Api[INVESTIGATOR_423507]:  The vaginal apex does not descend more than one -half into 
the vaginal canal (i.e. POP -Q point C < - 1/2 TVL) for multi -compartment 
prolapse or POPQ point C â‰¤ 0 for single compartment api[INVESTIGATOR_19529] l prolapse.  
2. Subjective success is achieved if the patient denies symptoms of vaginal bulging per 
PFDI -20 question 3, answering â€œnoâ€ or â€œyesâ€ but â€œNot at allâ€ bothersome (<2).  
3. No retreatment for POP:  no additional surgical treatment for POP in the segment(s) 
of the vagina treated at the index surgery or no pessary use since index surgery (i.e., 
â€˜treated segmentâ€™ refer to the target compartment).  
Additionally, a co- primary endpoint of the study is to achieve non- inferiority of mesh to 
native tissue repair fo r safety by [CONTACT_423546] [ADDRESS_534897] 
reported outcomes:  
1. Incidence of mesh erosion  
2. Incidence of mesh exposure  
3. Incidence of de novo dyspareunia  
4. Improvement in subject -related outcomes at 36 months compared to Baseline ((pelvic 
floor symptoms (PFDI -20), QOL (PF IQ-7), sexual functioning (PI[INVESTIGATOR_45220] -12) TOMUS 
pain scale)  
5. Assessment of subjectâ€™s level of improvement, measured by [CONTACT_423547] (PGI -I for Prolapse)  
6. Absence of re- intervention and re -surgery for recurrence of POP, persistence of 
disease, or mesh exposure/erosion  
7.  Surgical success based on the following composite outcome:  
a. Subjective success:  patient denies symptoms of vaginal bulging per PFDI -20 
question 3, answering â€œnoâ€ or â€œyesâ€ but â€œNot at allâ€ bothersome (<2)  
b. Anatomic success (in the operated compartment):  
â€¢ Anterior Segment:  No anterior prolapse at or beyond the hymen or 
POP-Q point Ba<0 
â€¢ Api[INVESTIGATOR_423509]:  The vaginal apex does not descend more than one -
half into the vaginal canal (i.e. POP -Q point C < 1/2 TVL) f or multi-
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 20 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 21 of 63 
  compartment prolapse or POPQ point C Ë‚ 0 for single compartment 
api[INVESTIGATOR_385303]. 
c. No retreatment for POP:  No additional surgical treatment for POP in the 
segment(s) of the vagina treated at the index surgery or no pessary use since 
index surgery 
8. Incidence of the following device or procedure -related AEs:  pelvic pain, infection, 
vaginal shortening, atypi[INVESTIGATOR_67260], neuromuscular problems, vaginal 
scarring, de novo vaginal bleeding, fistula formation and/or de novo voiding 
dysfunction  
8. Study Design  
This study is a prospective, non- randomized, parallel cohort, multi -center study conducted in 
partnership with the AUGS PFD Registry.   
The primary endpoint will be assessed once all per protocol subjects have completed the [ADDRESS_534898] to provide documentation of a minimum of 
10 procedures (i.e., native tissue repair procedure or Uphold/Uphold LITE procedure) prior 
to participation in order to document competency and experience.  Physician training, 
specialty, and site procedure location (such as outpatient in private- practice, institutional 
hospi[INVESTIGATOR_307], etc.) will be recorded.  
All efforts will be made to ensure all follow -up anatomic measurements (POP -Q) will be 
assessed by a healthcare provider to reduce treating surgeon bias on outcomes after the index 
procedure.  In the event the treat ing surgeon is the only qualified healthcare provider at the 
site trained in POP -Q assessments, the follow -up anatomic measurements will be performed 
by [CONTACT_176344].  
All enrolled subjects will have an anterior and/or api[INVESTIGATOR_423518].  Concomitant pr ocedures to 
treat a secondary defect can occur (including an anterior repair, posterior repair, 
hysterectomy, or sling placement for stress urinary incontinence), per physician discretion.  
Sling placement may include a synthetic material yet a concomitant  anterior repair or 
posterior repair cannot include a mesh implant.  An anterior colporrhaphy may be required, if 
clinically necessary.  All concomitant procedures performed will be recorded.  
Subjects who undergo a medical intervention (surgical or non -surgical) to treat recurrence, 
persistence of POP, or a mesh or suture complication will be followed to month 36 from the 
initial study procedure.  
8.1. Scale and Duration  
The study will be conducted at up to 40 sites at a rate of approximately 1- 2 subjects per 
month.  Sites will be encouraged to enroll a minimum of 10 subjects and up to a maximum of 
50 subjects.   
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 21 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 22 of 63 
  It is anticipated that approximately 414 subjects will be enrolled in total to achieve 330 
subjects (165 subjects per treatment arm) for the co -primary endpoint analysis at [ADDRESS_534899]-surgery to achieve non -inferiority of mesh to native tissue repair for safety by 
[CONTACT_423548] -related and device -related complications between 
baseline and the 36 month time point. Due to the pa rtnership with the PFD Registry, it is 
anticipated a portion of the control arm subjects will be shared from the Registry.   
The enrollment period is expected to be approximately 12 to 18 months after the final study 
center has been permitted to enroll sub jects.  A potential 20% â€œlost to follow -upâ€ rate is 
anticipated.   
Once enrolled into the study, subjects will be followed to [ADDRESS_534900]â€™s 
participation in the study is 36 months from time of procedure.  
Subjects who undergo a medical intervention (surgical or non -surgical) to treat recurrence, 
persistence of POP, or a mesh or suture complication will be followed to [ADDRESS_534901] the study Inclusion/Exclusion criteria and 
if eligible, enrolled into the study after providing Informed Consent.   
Study centers will be selected by [CONTACT_423549] a 
treatment center or a control center, depending on experience to reduce selection bias.  Some 
study centers may be selected to enroll a combination of treatment  and control subjects, 
depending on subject population and per [LOCATION_011] Scientific discretion.   
Treatment will occur after all Baseline procedures have been completed and the subject has 
been deemed eligible for the study.  Baseline procedures may be combin ed with the 
screening visit and may occur within three months prior to the study procedure, with 
confirmation of no evidence of infection prior to the procedure.  Due to the allowable 
window of up to three months between baseline and study procedure, the s tudy staff will 
confirm that subjects are still electing to undergo the study surgery with confirmation of no 
evidence of infection.  
8.2.1. Treatment and Control  
The treatment device in this study is Uphold Lightweight Vaginal Support System with 
transvaginal me sh (i.e., Uphold LITE).  Please refer to the Directions for Use document for 
device -specific information.  The surgical procedure steps will be standardized, including 
suture type (delayed absorbable or permanent sutures).  Physicians will be trained to th e 
standardized procedure steps prior to the first study procedure being performed.  Minor 
modifications to the standardization may be necessary based on a physicianâ€™s practice and 
patient care.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 22 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 23 of 63 
  The control procedure in this study is traditional native tiss ue repair, which includes 
sacrospi[INVESTIGATOR_423519]/or colporrhaphy.  The 
surgical procedure will be standardized, including suture type (delayed absorbable or 
permanent sutures). Sacrospi[INVESTIGATOR_11592] m ay be performed if the uterosacral 
ligaments are deemed unusable due to scarring or inability to access.  
9. Subject Selection  
9.1. Study Population and Eligibility  
This study will enroll adult, non- pregnant women who have been diagnosed with anterior 
and/or api [INVESTIGATOR_423520], and who may or may not 
also undergo a concomitant procedure (such as an anterior repair, posterior repair, 
hysterectomy, or sling placement for stress urinary incontinence).  If a concomitant 
proce dure were to occur, the sling placement should be a synthetic material, however the 
concomitant anterior or posterior repair cannot include a mesh implant.  An anterior 
colporrhaphy may be performed for cystocele repair, if clinically necessary.   
To assess for eligibility for this study, inclusion and exclusion criteria are included in 
Sections 9.2 and 9.3 below. 
9.2. Inclusion Criteria  
Subjects who meet all of the following criteria may be given consideration for inclusion in 
this clinical investigation, provided no exclusion criterion (see Section 9.3 ) is met.  
1. Subject is female  
2. Subject is â‰¥[ADDRESS_534902] has pelvic organ prolapse with the leading edge at or beyond the hymen. At 
or beyond the hymen is defined as POP -Q scores of Baâ‰¥ 0 (for prolapse of the 
anterior compartment alone) or Câ‰¥ 0 (for prolapse of the Api[INVESTIGATOR_423511]) 
or Câ‰¥ - 1/2 TVL and Baâ‰¥ 0 (for multi -compartment prolapse  that includes the anterior 
and api[INVESTIGATOR_423512])  
4. Subject reports of a bothersome bulge they can see or feel per PFDI -20, question 3 
response of 2 or higher (i.e. responses of â€œsomewhatâ€, â€œmoderatelyâ€, or â€œquite a bit)  
5. Subject or subjectâ€™s legally autho rized representative must be willing to provide 
written informed consent  
6. Subject is willing and able to comply with the follow -up regimen  
9.3. Exclusion Criteria  
Subjects who meet any one of the following criteria will be excluded from this clinical study.  
1. Subject is pregnant or intends to become pregnant during the study 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 23 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page [ADDRESS_534903] infection (UTI) or tissue necrosis  
3. Subject has history of pelvic organ cance r (e.g. uterine, ovarian, bladder, colo- rectal 
or cervical)  
4. Subject has had prior or is currently undergoing radiation, laser therapy, or 
chemotherapy in the pelvic area  
5. Subject has taken  systemic steroids (within the last month), or immunosuppressive or 
immunomodulatory treatment (within the last 3 weeks)  
6. Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus 
erythematosus (SLE), Marfans syndrome, Ehlers Danlos, collagenosis,  polymyositis, 
polymyalgia rheumatica)  
7. Subject has a k nown neurologic or medical condition affecting bladder function (e.g. 
multiple sclerosis, spi[INVESTIGATOR_1828], or stroke with residual neurologic deficit)  
8. Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse 
(colpoclesis)  
9. Subject has a previous prolapse repair with mesh in the target compartment  
10. Subject is planning to undergo a concomitant repair with use of mesh in the non-
target compartment 
11. Subject is not able to conform to the modified dorsal lithotomy position  
12. Subject has chronic systemic pain that involves the pelvic area or chronic focal pain 
that involves the pelvis pelvic pain)  
13. Subject has uncontrolled diabetes mellitus (DM)  
14. Subject is currently participating in or plans to participate in another device or drug  
during this study 
15. Subject has a known hypersensitivity to polypropylene mesh 
10. Subject Accountability  
10.1. Point of Enrollment  
Subjects will be considered enrolled in the study once an incision is made in the vaginal wall. 
All enrolled subjects will have been consen ted and assigned to receive either the treatment or 
control procedure per site assignment .  All enrolled subjects with a surgery initiated (i.e. 
incision in vagina) will be considered part of the Intent -to-Treat (ITT) population for the final 
study analysi s.  All ITT subjects who undergo the assigned study procedure and had no major 
protocol deviations will be considered part of the Per Protocol analysis.      
The following study timeline (see Table 10.1- 1) is based on milestones completed and the 
current follow -up visit cadence.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 24 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page 25 of 63 
  Table 10.1- 1: Study Timeline  
Milestone  Date   
Date of study initiation1 August [ADDRESS_534904] study site is â€œenrollment readyâ€ (i.e. IRB app roved, fully executed contract)   
2Assuming [ADDRESS_534905] patient visit completion.  
 
All efforts will be made by [CONTACT_299077] -up of patients and will 
follow a site -specific lo ss to follow -up plan.  These plans will include efforts such as 
telephone follow -up, Investigator -patient counseling, visit reminder tools, patient stipends if 
permitted per site budget, and/or other communication methods.   
10.2. Withdrawal  
All subjects enrolle d in the clinical study (including those withdrawn from the clinical study 
or lost to follow -up) will be accounted for and documented.  If a subject withdraws from the 
clinical investigation, the reason(s) will be recorded. Reasons for study withdrawal may  
include voluntary withdrawal (withdrew consent), involuntary withdrawal, lost to follow -up, 
subject death or other reasons to be documented on the Case Report Form.   
10.2.1. Voluntary Withdrawal  
Subjects may withdraw from the study at any time.  At the time of w ithdrawal, the 
Investigator shall document the reason for the withdrawal. For subjects who withdraw from 
the study and decide to revoke their authorization to use and disclose their medical 
information, the information that has already been collected in the study record may continue 
to be used; however, no new information will be obtained or added.   
10.2.2. Involuntary Withdrawal  
Subjects may be involuntarily withdrawn from the study if the Investigator determines it is in 
the subjectâ€™s best interest.   
10.2.3. Lost to F ollow -up 
Before a subject may be considered lost to follow -up the Investigator must make the 
following attempts to contact [CONTACT_423]:  
â€¢ Two documented telephone attempts  
â€¢ One certified letter  
If the subject is able to be reached and no longer wishes to participate in the study the 
Investigator shall document the reason for the withdrawal and complete End of Study Case 
Report Form.  If the subject is not able to be reached after the required att empts to contact [CONTACT_423550] . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 25 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI  
Confidential  Page [ADDRESS_534906]â€™s medical record the atte mpts to contact [CONTACT_423551].  
10.2.4. Subject Death 
Subjects may be withdrawn from the  study in the event of a death.  If any serious adverse 
event results in death  (regardless of the relatedness to the study device, procedure , or pelvic 
floor ), the event is to be documented in the source documentation, Case Report Form, and 
reported to [LOCATION_011] Scientific within the timeframe noted in Table 21.7- 1 (Investigator 
Reporting Requirements).  If an autopsy is conducted, a copy of the final autopsy report 
should be submitted to [LOCATION_011] Scientific  or designee.  The primary objective of the autopsy 
is to determine the cause of death, complications and othe r relevant findings.  The 
investigator will complete an End of Study Case Report Form and an adverse event (if 
applicable) per Section 11.6.   
10.2.5. Documentation of Ear ly Termination  
Once a subject withdraws from the study, the Case Report Form will be completed as 
appropriate up to the point of withdrawal and all Adverse Events shall be closed or 
documented as appropriate.  Withdrawn subjects (who had the study procedure initiated) will 
be included in the Intent -to-Treat analysis and will not be replaced.  
11. Study Methods  
11.1. Data Collection  
Study data will be collected per the schedule outlined in Table 11.1- 1.  All study data will be 
recorded on source documentation and captured within Case Report Forms for the purposes 
of this study  (see Section 13.1, Data Collection , Processing, and Review ).  Study data will be 
monitored by [CONTACT_423552] s and as applicable on a regular basis as 
outlined in the S tudy Monitoring Plan . 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 26 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AH  
Confidential  Page 27 of 63 
 Table 11.1- 1: Data Collection Schedule  
Procedure/Assessment  Screening/  
Enrollment Visit2 Pre-Operative/  
Baseline Visit  
  
Surgery  
 Discharge  Post-Operative Follow -up Visits7 
Month 2 Visit 
(Â± 4 Weeks) Month 6 Visit  
(Â± 4 weeks)  Month 12 Visit  
(-4/+ 12 weeks)   Month 18 Visit  
(-4/+ 12 weeks)   Month 24 Visit  
(-4/+ 12 weeks)   Month 36* Visit  
(-4/+12 weeks)  
Informed Consent  X          
Inclusion/Exclusion Criteria Review  X          
Demographics   X         
Urine Pregnancy Test  X X         
Physical Examination   X         
Medical History1  X         
Pelvic Exam with vaginal length 
measurement   X   X X X X X X 
Assessment of Infection (vaginal, bladder)     X X X X X X X 
Prolapse Grading (POP -Q Scoring)   X   X X X X X X 
PFDI -20 (Pelvic Floor Symptoms)   X   X X X X X X 
PFIQ -7 (Quality of Life)   X    X X X X X 
PI[INVESTIGATOR_45220] -12 (Sexual Functioning)   X    X X X X X 
PGI-I for Prolapse (Patient 
Improvement)       X X X X X 
TOMUS Pain Scale   X   X X X X X X 
SSQ -[ADDRESS_534907]-Operative Assessment4    X       
Assessment of Analgesic Intake   X   X X X X X X 
Assessment of Adverse Events6   X X X X X X X X 
Assessment of Risk Factors5  X   X X X X X X 
End of Study           X 
*Primary Endpoint  
1Medical History at baseline includes documented absence of UTI or other vaginal infection (i.e. vaginal culture, etc.).  
2The Screening/Enrollment Visit and Pre -Operative/Baseline Visit may be combined and occur up to 3 months prior to the study procedure with confirmed absence of infe ction.  
3Assessments include cystoscopy (at discretion of surgeon), estimated blood loss (EBL), assessment of concomitant procedures, and assessment of anesthesia type and duration of procedure.  
4Post-Operative Assessments include assessment of infection (wound, vaginal, bladder), voiding status, and date and time of dischar ge.   
5Assessment of Risk Factors includes menopausal stat us, estrogen use, age, smoking, diabetes status, BMI, hysterectomy status, concomitant procedures, surgeon training and exper ience . 
6All serious and non-serious device, procedure, and pelvic floor-related events , any other relevant events pertaining to the  pelvic region,  and any events resulting in death will be collected.  
7Every effort should be made to do the follow -up visit within the window; however, if this is not possible, the site should attempt to complete the visit as soon as possible but before the next 
visit window opens.  Follow -up visits will be considered missed once the visit window for the next follow -up visit opens.  For the Month [ADDRESS_534908] 
day of the visit window.  
 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 27 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AH  
Confidential  Page [ADDRESS_534909] requires a re -surgery during the study, please refer to the reduced table below for follow -up assessments.  Subjects 
undergoing re -interventions (non- surgical) continue with the study schedule as noted in Table 11.1- 1.  Additional data will be 
collected on subjects requiring a re -surgery, including a second procedure, mesh removal (as applicable), and second hospi[INVESTIGATOR_7954].  All subjects who are re- operated on will continue w ith their follow -up schedule until [ADDRESS_534910] their initial study 
procedure.    
Table 11.1- 2: Data Collection Schedule for Subjects Requiring a Re -Surgery  
Procedure/Assessment  Screening/  
Enrollment 
Visit  Pre-
Operative/  
Baseline 
Visit  Surgery  Discharge Post-Operative Follow -up Visits (Â± 4  Weeks)  
Month  2 Visit  
(Â± 4 Weeks)  Re-Surgery  Discharge Next Scheduled  
Follow -up Visit  
(-4/+12 weeks)  Month 36 
Visit**  
(-4/+12 
weeks)  
Informed Consent  X       
After  a re-surgery, 
subjects will return to the 
clinic on the date of their 
next regular study visit 
per the Schedule of 
Events table above.  
Subjects will continue to 
return for all scheduled 
Follow- up Visits until [ADDRESS_534911] their initial 
study procedure.   
Inclusion/Exclusion Criteria Review  X        
Demographics   X       
Urine Pregnancy Test  X X       
Physical Examination   X       
Medical History1  X       
Pelvic Exam with vaginal length 
measurement   X   X   X 
Assessment of infection (vaginal, bladder)     X X  X X 
Prolapse Grading (POP -Q Scoring)   X   X   X 
PFDI -20 (Pelvic Floor Symptoms)   X   X   X 
PFIQ -7 (Quality of Life)   X      X 
PI[INVESTIGATOR_45220] -12 (Sexual Functioning)   X      X 
PGI-I for Prolapse (Patient Improvement)         X 
TOMUS Pain Scale  X   X   X 
SSQ -[ADDRESS_534912]-Operative Assessment4    X      
Assessment of Analgesic Intake   X   X   X 
Assessment of Adverse Events6   X X X X X X 
Assessment of Risk Factors5  X   X   X 
End of Study         X 
 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 28 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 29 of 63 
 
  11.2. Study Candidate Screening  
Potential subjects will be identified by [CONTACT_423553]/or 
the Site Initiation Visit.   
Subjects will be screened against th e inclusion and exclusion criteria and, if confirmed to 
meet all requirements will be eligible to be consented for enrollment into the study.   
Subjects who do not meet the inclusion and exclusion criteria and/or are not enrolled into the 
study are conside red screening failures.  Information on screen failure subjects will be 
captured in the source documentation and screening logs and will include reason(s) for 
screen failure.  
11.3. Informed Consent  
Prior to any study- related assessments, each subject must sign an IRB- approved informed 
consent document to participate in the study as described in the Declaration of Helsinki and  
ISO [ZIP_CODE]:2011 (Clinical investigation of medical devices for human subjects -  Good 
clinical practice) and will be in accordance with all a pplicable laws and regulations.  The 
informed consent form will describe the planned and permitted uses, transfers, and 
disclosures of the subjectâ€™s personal health information. 
The subject or legally authorized representative (if approved by [CONTACT_1201])  will be given ample 
opportunity to inquire about details of the study to decide whether or not to participate in the 
study.  Copi[INVESTIGATOR_423521].  
Once the subject voluntarily agrees to participate in the study, then the Study Visit Schedule 
will be followed per below and as outlined in Table 11.1- 1 (Data Collection Schedule) .   
11.4. Study Visit Schedule  
The schedule of assessments is detailed in Table 11.1- 1 (Data Collection Schedule).  
11.4.1. Screening/Enrollment Visit  
The Screening/Enrollment visit may occur prior to the Pre -Operative/Baseline visit.  At this 
visit, the assessments below must be completed.   
â€¢ Informed c onsent  
â€¢ Review of inclusion/exclusion criteria  
11.4.2. Pre-Operative/Baseline Visit  
The Pre -operative/Baseline Visit will occur prior to the subject having surgery.  The 
assessments below must be completed prior to study surgery.  This visit may be combined 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 29 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 30 of 63 
 
  with the Screening/Enrollment Visit and occur up to 3 months prior to surgery with 
confirmed absence of infection.  
â€¢ Urine pregnancy test (for women of child -bearing potential only)  
â€¢ Medical history and physical examination:  assessment of  urinary tract infection 
(UTI) or other vaginal infection   
â€¢ Pelvic examination, vaginal length measurement  
â€¢ Prolapse grading (POP -Q scoring)  
â€¢ Assess baseline quality of life (PFIQ -7), sexual functioning (PI[INVESTIGATOR_45220] -12), pelvic floor 
symptoms (PFDI -20) 
â€¢ Assess baseline level of pain (TOMUS pain scale) and analgesic use  
â€¢ Assess baseline health status (EQ -5D) 
â€¢ Assessment of risk factors (includes menopausal status, estrogen use, age, smoking, 
diabetes status, body mass index, hysterectomy status, concomitant procedures, 
surgeon training and expertise)  
11.4.3. Surgery (â‰¤ 3 months from Baseline Visit)  
All procedures are to be performed with either Uphold LITE or native tissue repair, 
depending on which group to which the subject has been assigned.  Concomitant procedures 
including anterior or posterior repair or sling placement for stress urinary incontinence can 
occur, per physician discretion.  All c oncomitant procedures will be documented.   
â€¢ Study procedure  
â€¢ Cystoscopy, if clinically necessary  
â€¢ Estimated blood loss  
â€¢ Documentation of concomitant procedures    
â€¢ Document anesthesia type 
â€¢ Document duration of procedure  
â€¢ Assessment of adverse events (device,  procedure, or pelvic floor related)  
11.4.4. Discharge  
The subject may be discharged from the hospi[INVESTIGATOR_3491]/or treatment facility per standard of 
care and/or at the Investigatorâ€™s discretion.  Before the subject is discharged, the following 
assessments must be comp leted.  
â€¢ Assessment of infection (wound, vaginal, bladder)  
â€¢ Assessment of voiding status at discharge (i.e., subject discharged with indwelling 
catheter or performing self -catheterization to empty bladder or date/time of first void)  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 30 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 31 of 63 
 
  â€¢ Date and time of discharg e 
â€¢ Assessment of adverse events (device, procedure, or pelvic floor related)  
11.4.5. Follow -Up 
Subjects will be scheduled for follow -up visits as outlined in Table 11.1- 1 (Data  Collection 
Schedule).  The follow -up visit schedule begins from the day the subject is discharged (e.g. 
leaves hospi[INVESTIGATOR_307]/clinic) post -procedure and includes visit windows (counted in calendar 
days) .Every effort should be made to do the follow -up visit with in the window; however, if 
this is not possible, the site should attempt to complete the visit as soon as possible but before 
the next visit window opens.  Follow -up visits will be considered missed once the visit 
window for the next f ollow -up visit opens.  For the Month [ADDRESS_534913]â€™s home with their consent and if allowed by [CONTACT_423554]/EC.  If a home visit is not possible, every effort should be 
made to conduct as much of the visit as poss ible by [CONTACT_648] (i.e., assess adverse events, risk 
factors, and analgesic intake) and to send the subject questionnaires by [CONTACT_423555].  
11.4.6. Month 2 Visit (Â±4 Weeks)  
â€¢ Pelvic exam with vaginal length measurement  
â€¢ Assessment of infection (vaginal, bladder)  
â€¢ Prolapse g rading (POP -Q Scoring)  
â€¢ Assess pelvic floor symptoms (PFDI -20) 
â€¢ Assessment of pain (TOMUS pain scale) and analgesic intake 
â€¢ Assessment of adverse events (device, procedure, or pelvic floor related)  
â€¢ Assessment of risk factors  
11.4.7. Months 6, 12, 18, 24, 36 Visits (-4/+12 weeks)  
â€¢ Pelvic exam with vaginal length measurement  
â€¢ Assessment of infection (vaginal, bladder)  
â€¢ Prolapse g rading (POP -Q Scoring)  
â€¢ Assessment of pain (TOMUS pain scale) and analgesic intake 
â€¢ PFDI -20  
â€¢ PFIQ -7 
â€¢ PI[INVESTIGATOR_45220] -12 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 31 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 32 of 63 
 
  â€¢ PGI-I for Prolapse  
â€¢ SSQ-8 for s urgical satisfaction (Months 6, 12, 24, 36 only)  
â€¢ EQ-5D for health status (Months 12, 24, 36 only)  
â€¢ Assessment of adverse events (device, procedure, or pelvic floor related)  
â€¢ Assessment of risk factors  
â€¢ Study c ompletion (Month 36 only)  
All subjects who have c ompleted the study surgery and discharge will proceed to be followed 
through the above -outlined study visits to Month [ADDRESS_534914] completed the study.   
11.5. Re-Intervention/Re- Surgery  
It is the intention of this study to demonstrate an improvement in anterior/api[INVESTIGATOR_423522] a transvaginal prolapse repair kit .  However, it is 
recognized that during the course of the study, there is a possibility subjects may require a 
medical re- intervention for events including but not limited to failed prolapse repair, 
persistence of prolapse symptoms, or a mesh or procedure -related complication.  A re -
intervention may include surgical or non- surgical treatments and can occur for a medical 
complication or for prolapse recurrence. For the purpose of this study surgical interventions 
shall be classified as â€œre- surgeryâ€ and non- surgical interventions shall be classified as â€œre-
interventionsâ€.  Analyses will be performed to compare the rate of office -based interventions 
and of surgical interventions for medical complications and for prolapse recurrence in both 
treatment groups. 
Non-surgical interventions (re -interventions) are defined as office- based procedures and do 
not involve an operating room procedure.  Examples of non- surgical interventions may 
include but are not limited to an office visit to trim exposed mesh or suture in the vagina, a 
pessary, or physical therapy to treat procedural complications or persistent prolapse 
symptoms.  Data on non- surgical interventions will be captured in the CRFs.  Subjects will 
continue to be followed per the regular study visit schedule.   
Surgical interventions (re -surgery) are surgical operations performed to correct recurring 
prolapse symptoms, a procedural complication, or a mesh -related complication.  These 
surgical events typi[INVESTIGATOR_423523] a 
hospi[INVESTIGATOR_307].  The decision to perform a re -surgery for failed prolapse repair or persistence of 
prolapse symptoms will be per physician and subject discretion and all re -surgery data will 
be captured in the Case Report Forms.  All subjects defined as having a prolapse recurrence 
will be those who have anatomic and symptomatic failure of their prolapse surgery (prolapse 
beyond the hymen and symptoms of vaginal bulge).   
Subjects undergoing a re -surgery will be followed to [ADDRESS_534915] elects to not undergo re -
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 32 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page [ADDRESS_534916] Death  
If any serious adverse event results in death  (regardless of the relatedness to the stu dy device, 
procedure , or pelvic floor) , the event is to be documented in the source documentation, Case 
Report Form, and reported to the Sponsor within the timeframe noted in Table 21.7- 1 
(Investigator Reporting Requirements ).  If an autopsy is  conducted, a copy of the final 
autopsy report should be submitted to the Sponsor or designee.  The primary objective of the 
autopsy is to determine the cause of d eath, complications and other relevant findings.  
12. Statistical Considerations  
12.1. Endpoints  
12.1.1. Primary Endpoint  
The primary endpoint is an assessment of improvement in pelvic organ prolapse severity at 
36 months as compared to Baseline.  
[IP_ADDRESS]. Hypotheses  
Superiority testing for effectiveness will be performed for the primary hypothesis.    
Statistical testing will be performed to determine if composite endpoint of anatomic and 
symptomatic success rate in transvaginal mesh repair (treatment) group will be superior to 
traditional native tissue repair (control) group. The null hypothesis is that the success rate in 
treatment group is less than or equal to the success rate in control group:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¤ 0   
The alternative hypot hesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘> 0     
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ is the probability  of success in treatment group and control 
group respectively.  The rejection of null hypothesis indicates the superiority of t he treatment 
group over the control group. 
Statistical testing will be performed to determine if the overall complication rate (i.e. serious 
adverse device effects and serious procedure -related adverse events) of treatment group is 
non-inferior to the control group. The null hypothesis is that the complication rate in 
treatment group is greater than or equal to the rate in control group plus margin:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¥âˆ†   
The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  <âˆ†   
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 33 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 34 of 63 
 
  where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ are the overall complication rate in treatment group and 
control group respectively, and âˆ†  >0 is defined as the non- inferiority margin.  
[IP_ADDRESS]. Sample Size  
The statistical power calculation is based on a superiority assumption with a binary primary 
outcome. Success, based on a composite endpoint of anatomic and symptomatic success at 
36 month is assumed to be 70.0% for the native tissue arm and 85.0% for transvaginal mesh 
arm.17-21 With 2 -sided type I error of 0.05 and type II error of 0.1 (power 90%), 316 subjects 
(158 subjects per arm) are needed to detect 15% difference of transvaginal mesh to native 
tissue repair.   In addition to a superiority assumption, statistical testing will be performed for 
non-inferiority using a margin of - 12%.    
To assess for safety, the overall complication rate (i.e. serious adverse device effects and 
serious procedure -related adverse events) is anticipated to be approximately 14%.22 With 
type I error of 0.05 and type II error of 0.20 (power 80%), 298 subjects (149 subjects per 
arm) are needed to detect non -inferiority with a margin of 10%.    
To assess for office- based interventions for complications, the rate is anticipated to be 
approximately 2%.22 With type I erro r of 0.025 and type II error of 0.10 (power 90%), 330 
subjects (165 subjects per arm) are needed to detect non -inferiority with a margin of 5%.    
To assess for of surgical intervention for complications, the rate is anticipated to be 
approximately 1%.22 With type I error of 0.025 and type II error of 0.10 (power 90%), 260 
subjects (130 subjects per arm) are needed to detect non -inferiority with a margin of 4%.    
Non-surgical subjects will be enrolled by [CONTACT_423556].  Non -surgical subjects will not be enrolled into this clinical study.   Using the above 
calculations and assuming a 20% loss to follow -up rate, a total of 414 subjects (207 per study 
arm) will be enrolled to achieve the primary endpoint of success at 36 months.   
[IP_ADDRESS]. Statistical Methods  
For the primary efficacy endpoint, the comparisons of mesh repair to native tissue repair will 
be based on a two- sided 95% confidence interval for the treatment difference (mesh minus 
native tissue repair).  If the entire confide nce interval is above zero, superiority of mesh 
repair to native tissue repair will be demonstrated.  The confidence interval will be calculated 
based on the pooling of treatment differences across propensity score strata for a binary 
endpoint, as described in  Section  12.2.3 (Propensity Score Methodology) . 
If any data on the primary efficacy endpoint is missing, multiple imputation will be 
performed in which the missing values will be imputed five times under a logistic 
distribution model, using a fully conditional specification that includes the treatment arm and 
the assessments of the treatment success endpoint at each of 2, 6, 12 , 18, and 24 months.  As 
a sensitivity analysis, the comparison of treatments will also be performed using the 
following methods:  
â€¢ Tippi[INVESTIGATOR_18275]  
â€¢ Available cases only (i.e., only the subjects for whom the endpoint was assessed ) 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 34 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 35 of 63 
 
  For the primary safety endpoint, the proportions  will be calculated using for the numerator 
the number of subjects with an endpoint event and for the denominator the number of 
subjects in the analysis population (ITT and per protocol group).  Non -inferiority will be 
evaluated using a two- sided 90% confi dence interval for the treatment difference (mesh 
minus native tissue repair).  If the entire confidence interval is below the margin (10%), non-
inferiority will be demonstrated. The confidence interval will be calculated based on the 
pooling of treatment differences across propensity score strata for a binary endpoint, as 
described in Section 12.2.3 (Propensity Score Methodology).  
12.1.2. Secondary  Endpoints  
Secondary endpoints will be to evaluate mesh -related complications and subject reported 
outcomes as safety endpoints between baseline and 36 months:  
1. Incidence of mesh erosion  
2. Incidence of mesh exposure  
3. Incidence of de novo dyspareunia  
4. Improvement in subject specific out comes at 36 months compared to Baseline (pelvic 
floor symptoms (PFDI -20), QOL (PFIQ -7), sexual functioning (PI[INVESTIGATOR_45220] -12), TOMUS 
pain scale)  
5. Assessment of subjectâ€™s level of improvement, measured by [CONTACT_423547] (PGI -I for Prolapse)  
6. Absence of re- intervention or re -surgery for recurrence or persistence of POP or mesh 
exposure/erosion  
7. Surgical success based on the following composite outcome:  
a. Subjective success:  patient denies symptoms of vaginal bulging per PFDI -20 
question 3, answering â€œnoâ€ or â€œyesâ€ but â€œNot at allâ€ bothersome (<2)  
b. Anatomic success (in the operated compartment):  
â€¢ Anterior Segment:  No anterior prolapse at or beyond the hymen or 
POP-Q point Ba<0 
â€¢ Api[INVESTIGATOR_423509]:  The vaginal apex does not descend more than one -
half into the vaginal canal (i.e. POP -Q point C < 1/2 TVL) for multi-
compartment prolapse or POPQ point C Ë‚ 0 for single compartment 
api[INVESTIGATOR_385303]. 
c. No retreatment for POP:  No additional surgical treatment for POP in the 
segment(s) of the vagina  treated at the index surgery or no pessary use since 
index surgery 
8. Device or procedure -related incidence of the following:  pelvic pain, infection, 
vaginal shortening, atypi[INVESTIGATOR_67260], neuromuscular problems, vaginal 
scarring, de novo vaginal bleeding, fistula formation and/or de novo voiding 
dysfunction  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 35 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 36 of 63 
 
  Definitions for the above listed adverse events are included in Section 21.2  (Definitions and 
Classifications) .  Rates of incidence for the adverse events will be stratified by [CONTACT_423557].   
[IP_ADDRESS]. Hypotheses  
Statistical testing will be performed to determine if the de novo dyspareunia rate of treatment 
group is non -inferior to the control group.  The null hypothesis is that the de novo 
dyspareunia rate in treatment group is greater than or equal to the rate in control group plus 
margin:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¥âˆ†   
The alter native hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  <âˆ†   
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ are the de novo dyspareunia rate in treatment group and 
control group respectively, and âˆ†  >0 is defined as the non- inferiority margin.  
Statistical testing will be performed to determine if the AE incidences (pelvic pain, infection, 
vaginal shortening, atypi[INVESTIGATOR_67260], neuromuscular problems, vaginal scarring, de 
novo vaginal bleeding, fistula formation and/or de novo voiding dys function) rate of 
treatment group is non- inferior to the control group.  The null hypothesis is that the AE 
incidences rate in treatment group is greater than or equal to the rate in control group plus 
margin:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¥âˆ†   
The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  <âˆ†   
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ are the AE incidence rates in treatment group and control 
group respectively, and âˆ† >0 is defined as the non -inferiority margin. 
The propensity score adjusted confidence intervals described in Section 12.2.3. (Propensity 
Score Methodology) will be used to summarize the mean score improv ement of Quality of 
Life (PFIQ, PFDI, PI[INVESTIGATOR_45220], TOMUS pain scale) of the mesh (treatment) group compared to that 
of the native repair (control) group . 
[IP_ADDRESS]. Sample Size  
The rate of de novo dyspareunia is anticipated to be approximately 9%.24  With type I error 
of 0.05 and type II error of 0.20 (power 80%), 326 subjects (163 subjects per arm) are needed 
to detect non- inferiority with a margin of 7.9%.    
The rate of AE incidence (pelvic pain, infection, vaginal shortening, atypi[INVESTIGATOR_423524], neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula 
formation and/or de novo voiding dysfunction) is anticipated to be approximately 12%.22  
With type I error of 0.05 and type II error of 0.20 (power 80%), 330 subjects (165 s ubjects 
per arm) are needed to detect non -inferiority with a margin of 8.9%.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 36 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 37 of 63 
 
  [IP_ADDRESS]. Statistical Methods  
A comparison of data for all subjects will be included per the following statistical analyses to 
measure for secondary endpoints:  
â€¢ Rate of adverse device or procedural -related effects within 6, 12, 18, 24 and 36 
months  
â€¢ Overall rate of adverse device or procedural -related effects within 6, 12, 18, 24, 36 
months  
â€¢ Comparison of adverse device or procedural -related effects between treatment groups 
â€¢ Rate and severity  of mesh exposure and erosion within 6, 12, 18, 24, 36 months  
â€¢ Assessment of rate of adverse device or procedural -related effects in subjects with 
reoperation for failed prolapse repair  
â€¢ Assessment of rates of/times to reoperation  
â€¢ Comparison of rate of adver se device or procedural -related events in subjects with re -
surgery in both treatment groups  
â€¢ Assessment and comparison between groups of analgesic intake and pain scoring at 
post-operative [ADDRESS_534917] for each group on all patients and with the propensity 
score adjusted confidence intervals for the pain score differences between groups .  
Change in analgesic intake from baseline will be analyzed by [CONTACT_303583]â€™s test for 
each group on all patients.  
â€¢ Assessment of severe blood loss during surgical procedure  
â€¢ Duration of surgery from operative report  
â€¢ Assessment of re- treatment interventions (i.e. surgery, office -procedure, etc.)  
â€¢ Assessment of days to discharge and return to normal activi ty 
â€¢ Assessment of risk factors, including menopausal status, estrogen use, age smoking, 
diagnosis of diabetes, body mass index, concomitant procedures, surgeon training and 
experience  
A comparison of data between baseline and 36 months for all subjects wil l be included per 
the following statistical analyses to measure for secondary endpoints:  
â€¢ Quality of Life Assessments (PFIQ, PFDI, PI[INVESTIGATOR_45220], TOMUS) at 6, 12, 18, 24, 36 
months as compared to baseline: paired t -test will be used to compare mean QOL 
score improve ment from baseline to 6, 12, 18, 24 and 36 months for each group.  
â€¢ Comparison of Quality of Life Assessments improvements between treatment groups 
â€¢ Assessment of Quality of Life in subjects w ith re -surgery after re -surgery  
â€¢ Assessment of subject satisfaction at 6, 12, 18, 24, 36 months (PGI -I for Prolapse)  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 37 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 38 of 63 
 
  Propensity score adjusted confidence intervals described in Section 12.2.3 (Propensity Score 
Metho dology) will be used to evaluate continuous variables including QOL score 
improvements between two groups.  
12.2. General Statistical Methods 
12.2.1. Analysis Sets  
The Intent -to-Treat (ITT) subject population includes all subjects who provide written 
informed consent to be enrolled into the study and have a surgery initiated (i.e. incision in 
vagina) regardless of their adherence with the entry criteria, regardless of treatment and 
withdrawal/protocol deviations.  
The treated population includes all subjects who undergo a  study surgical procedure.  The 
subject is defined to have successfully completed the surgical procedure (i.e. prolapse repair 
successful) and discharged.  
The Per Protocol (PP) population includes all subjects in the ITT Population who received 
the assigne d treatment and had no major protocol deviations.  
All primary and secondary endpoints will be analyzed on the ITT Population.  The primary 
safety and n on-safety endpoints will also be analyzed on the per -protocol population.  
12.2.2. Control of Systematic Error/Bi as 
To reduce selection bias in this non- randomized study, each study center will be permitted to 
enroll subjects in only one of the treatment groups.  Physicians will be selected based on 
device and clinical research experience and the decision as to which  device to implant in 
subjects prior to study initiation at each center.  Some study centers may be permitted per 
[LOCATION_011] Scientific to enroll subjects in both treatment and control groups.  All decisions will 
be documented prior to subject enrollment.  All  subjects meeting the eligibility criteria at the 
study center will be screened and enrolled as applicable.  
Propensity score stratification will be utilized to address the potential imbalance in risk 
factors between groups, described in Section 12.2.3 (Propensity Score Methodology) .  This 
analysis will be performed blind to all clinical outcome data and prior to performing any 
analysis of endpoints.  
12.2.3. Propensity Score Methodology 
Analyses comparing the treatment groups will be adjusted for the propensity score.  The 
propensity score is the probability that the subject enrolled in the mesh arm rather than the 
native tissue (control) arm, given the characteristics of the  subject and center. The 
characteristics identified are as follows: age, race, body mass index, smoking, diabetes, post -
menopausal, prior prolapse repair, prior hysterectomy, estrogen use, POP -Q C measurement, 
POP-Q Ba measurement, POP -Q Bp measurement, co ncomitant repair for stress urinary 
incontinence, and surgeon case volume.  Logistic regression of both treatment arm s (i.e., 
(transvaginal mesh repair vs. native tissue repair)  on these characteristics will be used to 
estimate the propensity score.  The s ubjects will then be partitioned into five strata 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 38 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 39 of 63 
 
  corresponding to quintiles of the propensity score.  If the balance between treatment arms 
within the strata is deemed adequate, the treatment difference adjusted for propensity score 
stratum will be estima ted as described in the following. 
The propensity adjusted treatment difference will be based on averaging the treatment 
differences of the propensity score strata.  For a binary outcome, the within- stratum treatment 
difference is ğ·ğ· ğ‘—ğ‘—=ğ‘ğ‘ğ‘‡ğ‘‡ğ‘—ğ‘—âˆ’ğ‘ğ‘ğ¶ğ¶ğ‘—ğ‘—, where  ğ‘ğ‘ğ‘‡ğ‘‡ğ‘—ğ‘— and ğ‘ğ‘ğ¶ğ¶ğ‘—ğ‘— is the proportion of treatment and control 
subjects, respectively, in stratum j . The variance of ğ·ğ·ğ‘—ğ‘— is approximately  
ğ‘‰ğ‘‰ğ‘—ğ‘—=ğ‘ğ‘ğ‘‡ğ‘‡ğ‘—ğ‘—(1âˆ’ğ‘ğ‘ğ‘‡ğ‘‡ğ‘—ğ‘—)
ğ‘›ğ‘›ğ‘‡ğ‘‡ğ‘—ğ‘—+ğ‘ğ‘ğ¶ğ¶ğ‘—ğ‘—(1âˆ’ğ‘ğ‘ğ¶ğ¶ğ‘—ğ‘—)
ğ‘›ğ‘›ğ¶ğ¶ğ‘—ğ‘— 
Denoting the number of subjects in stratum j  by ğ‘›ğ‘›ğ‘—ğ‘—=ğ‘›ğ‘›ğ‘‡ğ‘‡ğ‘—ğ‘—+ğ‘›ğ‘›ğ¶ğ¶ğ‘—ğ‘— , the treatment difference 
will be estimated by [CONTACT_941] (weighted) mean of the within- stratum treatment differences  
ğ·ğ·=ï¿½ğ‘›ğ‘›ğ‘—ğ‘—
ğ‘›ğ‘›ğ·ğ·ğ‘—ğ‘—
ğ‘—ğ‘— 
where ğ‘›ğ‘› =âˆ‘ğ‘›ğ‘›ğ‘—ğ‘—ğ‘—ğ‘— is the total sample size across all strata and study arms. D  is approximately 
normally distributed with variance  
ğ‘‰ğ‘‰=ï¿½ï¿½ğ‘›ğ‘›ğ‘—ğ‘—
ğ‘›ğ‘›ï¿½2
ğ‘‰ğ‘‰ğ‘—ğ‘—
ğ‘—ğ‘— 
from which a confidence interval for the true treatment difference will be constructed . For 
each continuous outcome , the confidence interval will be constructed similarly, with D  and V  
obtained as above with the treatment difference within each stratum replaced by ğ·ğ·ğ‘—ğ‘—=ğ‘‹ğ‘‹ï¿½ğ‘‡ğ‘‡ğ‘—ğ‘—âˆ’
ğ‘‹ğ‘‹ï¿½ğ¶ğ¶ğ‘—ğ‘— , where ğ‘‹ğ‘‹ï¿½ğ‘‡ğ‘‡ğ‘—ğ‘— and ğ‘‹ğ‘‹ï¿½ğ¶ğ¶ğ‘—ğ‘— , respectively, is the mean of the treatment and control subjects, and  
ğ‘‰ğ‘‰ğ‘—ğ‘—=ğ‘†ğ‘†ğ‘‡ğ‘‡2
ğ‘—ğ‘—
ğ‘›ğ‘›ğ‘‡ğ‘‡ğ‘—ğ‘—+ğ‘†ğ‘†ğ¶ğ¶2
ğ‘—ğ‘—
ğ‘›ğ‘›ğ¶ğ¶ğ‘—ğ‘— 
where ğ‘†ğ‘†ğ‘‡ğ‘‡2
ğ‘—ğ‘— and ğ‘†ğ‘†ğ¶ğ¶2
ğ‘—ğ‘— are the variances of the treatment and control subjects in stratum j . 
12.3. Data Analyses  
Presentation of summary statistics for continuous variables will include N, mean, median, 
standard deviation, minimum, and maximum values for non- missing data.  For catego rical 
variables, the number and percentage under each category for non- missing data will be 
presented.  
Additionally, subjects meeting this studyâ€™s eligibility criteria under the PFD Registry may be 
included in the analyses plan.  The intention is to utiliz e a shared control arm from the PFD 
Registry.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 39 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 40 of 63 
 
  12.3.1. Rate of Office -Based Intervention for Recurrence 
Statistical testing will be performed to determine if the rate of office -based intervention for 
recurrence in the treatment group will be superior to the control  group.  The null hypothesis 
is that the rate of office -based intervention for recurrence in treatment group is greater than 
or equal to the rate in control group:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  â‰¥0   
The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ <0   
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡  
 and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ are the office -based intervention rates for recurrence  in 
treatment group and control group respectively.  The rejection of null hypothesis indicates 
the superiority of the treatment group over the control group.  
12.3.2. Rate of Surgical Intervention for Recurrence  
Statistical testing will be performed to determine if the rate of surgical intervention for 
recurrence in treatment group will be superior to the control group.  The null hypothesis is 
that the rate of surgical intervention for recurrence in treatment group is greater than or equal 
to the rate in control group:   
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  â‰¥0   
The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ <0    
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡  
 and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ are the surgical intervention rates for recurrence in treatment 
group a nd control group respectively.  The rejection of null hypothesis indicates the 
superiority of the treatment group over the control group. 
The propensity score adjusted analysis described in Section 12.2.3 (Propensity Score 
Methodology) will be used for testing the null hypothesis and computing the confidence 
intervals for rate of office -based intervention for recurrence and surgical intervention for 
recurrence between treatment group and control group.  
12.3.3. Rate of Office -Based Intervention for Complications  
Statistical testing will be performed to determine if the rate of office -based intervention for 
complications in the mesh (treatment) group is non -inferior to the native tissue repair 
(control) group.  The null hypothesis is that the rate  of office -based intervention for 
complications in treatment group is greater than or equal to the rate in control group plus 
margin:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¥âˆ†   
The alternative hypothesis is:    
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ <âˆ†   
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 40 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 41 of 63 
 
  where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ are the office- based intervention rates for complication in 
treatment group and control group respectively, and âˆ†  >0 is defined as the non -inferiority 
margin. 
The rate of office- based intervention f or complication is anticipated to be approximately 
2%.  With type I error of 0.025 and type II error of 0.10 (power 90%), 330 subjects (165 
subjects per arm) are needed to detect non -inferiority with a margin of 5%.    
12.3.4. Rate of Surgical Intervention for Comp lications  
Statistical testing will be performed to determine if the rate of surgical intervention for 
complications of the mesh (treatment) group is non- inferior to the native tissue repair 
(control) group.  The null hypothesis is that the rate of surgical  intervention for complications 
in treatment group is greater than or equal to the rate in control group plus margin:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¥âˆ†   
The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  <âˆ†   
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ are the probabilities of having surgical intervention for 
complication in treatment group and control group respectively, and âˆ† >0 is defined as the 
non-inferiority margin.  
The rate of surgical intervention complica tion is anticipated to be approximately 1%.  With 
type I error of 0.025 and type II error of 0.10 (power 90%), 260 subjects (130 subjects per 
arm) are needed to detect non -inferiority with a margin of 4%.    
The propensity score adjusted analysis described in Section 12.2.3 (Propensity Score 
Methodology) will be used for testing the null hypothesis and computing the confidence 
intervals for rate office -based interven tion for complication and surgical intervention for 
complication between treatment group and control group.  
For each group, logistic regression will be performed, to include office -based intervention for 
recurrence as a covariate for analyzing the primary endpoint (success rate of improvement in 
pelvic organ prolapse at 36 months) data.  
For each group, Cox regression will be performed, to include surgical intervention for 
recurrent prolapse as a covariate for analyzing adverse events (pelvic pain, infection, vaginal 
shortening, vaginal scarring, de novo vaginal bleeding, fistula formation and/or de novo 
voiding dysfunction) data. 
Descriptive statistics for the baseline characteristics and QOL outcome for the non -surgery 
(i.e. pessary) group will be summarized from the AUGS PFD  Registry  Level 1/2 database.  
12.3.5. Sub- Analysis for Sling Repair and Interventions for Recurrence  
[IP_ADDRESS]. Subjects with only POP repair and those  with sling and prolapse repair   
A two sample t -test will be performed in pain score change from  baseline to each follow -up 
visit within mesh or native tissue repair group, to compare groups with and without SUI 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 41 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 42 of 63 
 
  surgery.  Using this method of analysis will make it less difficult to assess causality for 
adverse events, including pain.  
[IP_ADDRESS]. Subjects with of fice-based intervention for recurrence  
Adverse procedural/device event rates and QOL information will be collected for [ADDRESS_534918] has office- based intervention for recurrence.    
Event rate for each of device -relate d or procedure -related adverse events of specified AE 
type (mesh erosion, mesh exposure, dyspareunia) during the period after the intervention will 
be summarized by [CONTACT_1570].  Treatment groups will be compared using Cox 
regression for the event -free survival time (starting at the time of first office based 
intervention) with treatment arm .   
For each QOL instrument, a comparison using a t-test will be performed between native 
tissue repair and mesh group on the basis of QOL score at the first schedul ed follow -up after 
office -based intervention for recurrence.  
A two sample t -test will be used to compare groups with office -based intervention for 
recurrence and without intervention within each treatment group.  QOL score change will be 
reported from the  last follow -up visit before office -based intervention for recurrence, to the 
next scheduled follow -up visit after office -based intervention for recurrence within each 
treatment group.  For those subjects without recurrence, we will use baseline as the â€œbeforeâ€ 
time point in analysis, and the QOL data at 6 month follow -up visit as the â€œafterâ€ time point.  
Similarly, event rate for each adverse device and procedure -related event type specified 
(mesh erosion, mesh exposure, dyspareunia)  will be compared  betwe en subjects with office -
based intervention for recurrence and those without.  This will be done using a Cox 
regression of time to the first onset of each adverse event after the starting time to compare 
groups with office -based intervention for recurrence and within each treatment group.  The 
starting time will be baseline f or those subjects without intervention, and time of office -based 
intervention for recurrence for those with intervention.  
[IP_ADDRESS]. Subjects with surgical intervention for recurrence  
The above mentioned analyses for the subgroup with office based intervention for recurrence 
will be repeated for s ubjects with  surgical intervention for recurrence.  
[IP_ADDRESS]. Subjects with surgical intervention for recurrence  or complications  
Each of device -related or procedure -related adverse events during the period after the re-
surgery will be summarized by [CONTACT_423558](s) (i.e. api[INVESTIGATOR_423525], anterior only, 
api[INVESTIGATOR_423526]) treated in the index procedure within each treatment group. 
12.3.6. Additional Data A nalyses  
â€¢ Assessment of EQ -5D score for health status at 12, 24 and 36 month as compared to 
baseline  
â€¢ Assessment of SSQ -8 score for surgical satisfaction at 6, 12, 24 and 36 month  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 42 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 43 of 63 
 
  Propensity score adjusted confidence intervals described in Section 12.2.3 (Propensity Score 
Methodology) will be used to summarize EQ -5D and SSQ -[ADDRESS_534919] enrolled in the 
study; all subjects will be followed to [ADDRESS_534920] of the primary and some or all of the secondary endpoints and 
demographics if dee med necessary.   
Descriptive statistics by [CONTACT_423559] 95% confidence interval for the treatment 
difference will be reported after adjusting for propensity scores.  The descriptive statistics 
includes mean, standard deviation, n, minimum, and maximum for continuous variables and 
frequency statistics for discrete variables1. 
[IP_ADDRESS]. Hypotheses2 
The interim analysis hypothesis is that t ransvaginal mesh repair (treatment) is non -inferior to 
traditional native tissue repair (control)  in both effectiveness and safety  at 12 months .   
Statistical testing will be performed to evaluate whether transvaginal mesh repair  (treatment) 
is non- inferior to native tissue repair with respect to the  composite  treatment success 
endpoint.  The null hypothesis is that the suc cess rate for Uphold LITE is inferior to that of 
the control at a non- inferiority margin of 12% : 
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¤ âˆ’12% 
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ is the success rate in the treatment and control group, 
respectively.  The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘> âˆ’12%      
The rejection of null hypothesis indicates the non -inferiority  of transvaginal mesh repair.  
If non- inferiority is demonstrated , then the superiority of transvaginal mesh repair at 12 
months will be evaluated, for which the hypotheses are:  
                                                 
 
1 To support [LOCATION_002] Premarket Approval Activities, as agreed to on the Presubmission call held on May 
24, 2017 ( Q170382 ), [LOCATION_011] Scientific will submit descriptive statistics for the submission of the PMA, which 
per reclassification document number 2 015-[ZIP_CODE] , is required to be accepted and filed on or before July 5, 
2018.  
2 To support the continued review of the Premarket Approval Application for the [LOCATION_002], [LOCATION_011] 
Scientific will submit hypothesis testing as an Amendment to the initial PMA fo llowing acceptance and filing.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 43 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 44 of 63 
 
  ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ â‰¤ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ 
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ > ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  
The rejection of null hypothesis indicates the superiority  of transvaginal mesh repair.  
Statistical testing will b e performed to determine if the serious complication rate (i.e. serious 
adverse device effects and serious procedure -related adverse events) of the treatment group is 
non-inferior to the control group  at 12 months . The nul l hypothesis is that the serious 
complication rate in treatment group is greater than or equal to the rate in control group plus 
margin  of 10 %: 
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ â‰¥10%   
where ğœ‹ğœ‹ ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡   and ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘ is the seriou s complication rate in the treatment group  and 
control group, respectively. The alternative hypothesis is:  
ğ»ğ»ğ»ğ»: ğœ‹ğœ‹ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ âˆ’ğœ‹ğœ‹ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘ğ‘ğ‘ğ‘  <10%    
[IP_ADDRESS]. Statistical Methods  
The comparisons of mesh repair to native tissue repair will be based on a two -sided 90 % 
confidence interval for the treatment difference.   The confidence interval will be calculated 
based on the pooling of treatment differences across propensity score strata for a binary 
endpoint, as described in Section 12.2.3 (Propensity Score Methodology).  
Missing 12 month data for the composite efficacy endpoint will be handled by [CONTACT_423560] a logistic regression model using a fully conditional specification .  The 
imputation model  will include treatment group and primary efficacy outcome at 2 and 6 
month.  A total of 5 imputed data sets will be generated.  
The following methods will also be used as sensitivity analy ses: 
â€¢ Observed data only  
â€¢ Tippi[INVESTIGATOR_18275]  
12.3.9. Justification of Pooling  
The analyses will be presented using pooled data across institutions.  For each group, an 
analysis of the poolability will be made using logistic regression for binary outcomes, or 
analysis of variance for continuous outcomes, to assess differences between study institutions 
and to justify pooling data across institutions.  Centers with less than [ADDRESS_534921] reported outcomes.  Possible predictors may include, but not 
limited to, demographic /baseline data and risk factors data.  Factors from the univariate 
model with pâ‰¤0.20 will also be put into multivariate model using a stepwise procedure in a 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 44 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 45 of 63 
 
  logistic regression model.  The significance thresholds for entry and exit into the model will 
be set to p<0.10.  Analysis of Covariance (ANCOVA) will be performed for subject reported 
outcome with appropriate predictors.  
13. Data Management 
13.1. Data Collection, Processing, and Review  
Good Clinical Practice Guidelines require that investigators maintain information (i.e., 
Source Data) in the subjectâ€™s medical records, laboratory reports, clinic charts, etc. (i.e., 
Source Documents) that corresponds to data recorded on the Case Report Forms.  In order to 
comply with these requirements, the following information should be maintained as source 
documentation, including but not limited to:  
â€¢ Medical history/physical condition of the subject before enrollment  
â€¢ Protocol entry criteria  
â€¢ Dated and signed notes for specific results of procedures and exams  
â€¢ Laboratory reports  
â€¢ Information related to adverse device effects 
â€¢ Surgical notes, including subject condition and re -surgery if applicable  
â€¢ Quality of life assessments and TOMUS pain scales  
â€¢ Discharge Summaries/Procedure reports  
â€¢ Autopsy reports  
Subject data will be recorded on Case Report Forms which will be provided by [CONTACT_423561].  The Source Data r eported on the Case Report Forms shall 
be derived from source documentation and shall be consistent with these source documents.  
Any discrepancies shall be explained and documented.  Any change or correction made to 
the clinical data will be dated, initialed, and explained, if necessary, and shall not obscure the 
original entry.  An audit trail shall be maintained which will be made available for review by  
[CONTACT_400954].  Any queries to the data will be addressed by [CONTACT_423562] a timely manner.  
13.2. Data Retention  
The investigator will maintain, at the investigative site, in original format all essential study 
documents a nd source documentation that support the data collected on study subjects in 
compliance with ISO [ZIP_CODE]:2011 (Clinical investigation of medical devices for human 
subjects -  Good clinical practice) .  Documents must be retained for at least [ADDRESS_534922].  These documents will be retained 
for a longer period of time by [CONTACT_423563].  It is [LOCATION_011] Scientific â€™s responsibility to inform the investigator when 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 45 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page [ADDRESS_534923], or scientific integrity of the data, an amendment is required. 
Appropriate approvals (e.g., IRB/EC/FDA/CA) of the revised protocol must be obtained 
prior to implementation.  
15. Deviations  
An Investigator must not make any changes or deviate from this protocol, except to protect 
the life and physical well -being of a subject in an emergency. An investigator shall notify 
[LOCATION_011] Scientific and the reviewing IRB/EC of any deviation from the investigational plan to 
protect the life or physical well -being of a subject in an emergency, and those deviations 
which affect the scientific integrity o f the clinical investigation. Such notice shall be given as 
soon as possible, but no later than [ADDRESS_534924] be documented and reported to [LOCATION_011] Scientific .  Study centers may also 
be required to report deviations to their IRB/EC, per local guidelines and government 
regulations.  
Deviations will be reviewed and evaluated on an ongoing basis and, as necessary, appropriate 
corrective and preventive actions (including notification, center re -training, or 
discontinuation) will be put into place by [CONTACT_5756] . 
16. Device/Equipment Accountability  
This is a post -market study and therefore no investigational devices are being used.  All 
commercial and institutional policies regarding but not limited to device use, purchase and/or 
storage will be followed.  
17. Compliance 
17.1. Statement of Compliance  
This study will be conducted in accordance with ISO [ZIP_CODE]:2011 (Clinical investigation of 
medical devices for human subjects -  Good clinical practice), ethical principles that have 
their origins in the Declaration of Helsinki, and pertinent individual country laws an d 
regulations.  The study shall not begin until the required approval/favorable opi[INVESTIGATOR_423527] . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 46 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 47 of 63 
 
  IRB/EC and/or regulatory authority has been obtained, as appropriate.  Any additional 
requirements imposed by [CONTACT_1201]/EC or regulatory authority shall be followed, if 
appropriate.  
17.2. Investigator Responsibilities  
The Principal Investigator [INVESTIGATOR_123318], the investigational 
plan/protocol, ISO [ZIP_CODE]:2011 (Clinical investigation of medical devices for human subjects 
- Good clinical practice) , ethical principles that have their origins in the Declaration of 
Helsinki, any conditions of approval imposed by [CONTACT_3488]/EC, and prevailing local 
and/or country laws and/or regulations, whichever affords the greater protection to the 
subject.  
The Principal Investigatorâ€™s responsibilities include, but are not limited to, the following.  
â€¢ Prior to beginning the study, sign the Investigator Agreement and Protocol Signature 
[CONTACT_71660]/her agreement to conduct the study in accordance with the 
protocol.  
â€¢ Provide his/her qualifications and experience to assume responsibility for the proper 
conduct of the study and that of key members of the center team through up- to-date 
curriculum vitae or other relevant documentation and disclose potential conflicts of 
interest, including financial, that may interfere with the conduct of the clinical study 
or interpretation of results.  
â€¢ Make no changes in or deviate fro m this protocol, except to protect the life and 
physical well -being of a subject in an emergency; document and explain any 
deviation from the approved protocol that occurred during the course of the clinical 
investigation. 
â€¢ Create and maintain source documents throughout the clinical study and ensure their 
availability with direct access during monitoring visits or audits; ensure that all 
clinical -investigation -related records are retained per requirements.  
â€¢ Ensure the accuracy, completeness, legibility, and timeliness of the data reported to 
[LOCATION_011] Scientific in the CRFs and in all required reports.  
â€¢ Record, report, and assess (seriousness and relationship to the device/procedure) 
every adverse event and observed device deficiency. 
â€¢ Report to [LOCATION_011] Scientific , per the protocol requirements, all SAEs and device 
deficiencies that could have led to a SADE.  
â€¢ Report to the IRB/EC and regulatory authorities any SAEs and device deficiencies 
that could have led to a SADE, if required by [CONTACT_423564]/EC, and supply [LOCATION_011] Scientific with any additional requested 
information related to the safety reporting of a particular event.  
â€¢ Allow [LOCATION_011] Scientific or its designee to perform monitoring and auditing activities, 
and be accessibl e to the monitor and respond to questions during monitoring visits.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 47 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 48 of 63 
 
  â€¢ Allow and support regulatory authorities and the IRB/EC when performing auditing 
activities.  
â€¢ Ensure that informed consent is obtained in accordance with this protocol and local 
IRB/EC requ irements.  
â€¢ Provide adequate medical care to a subject during and after a subjectâ€™s participation 
in a clinical study in the case of adverse events, as described in the Informed Consent 
Form (ICF).  
â€¢ Inform the subject of the nature and possible cause of any a dverse events 
experienced.  
â€¢ Inform the subject of any new significant findings occurring during the clinical 
investigation, including the need for additional medical care that may be required.  
â€¢ Ensure that clinical medical records are clearly marked to indic ate that the subject is 
enrolled in this clinical study. 
â€¢ Ensure that, if appropriate, subjects enrolled in the clinical investigation are provided 
with some means of showing their participation in the clinical investigation, together 
with identification an d compliance information for concomitant treatment measures 
(contact [CONTACT_5735]).  
â€¢ Inform, with the subjectâ€™s approval or when required by [CONTACT_2091], the 
subjectâ€™s personal physician about the subjectâ€™s partic ipation in the clinical 
investigation. 
â€¢ Make all reasonable efforts to ascertain the reason(s) for a subjectâ€™s premature 
withdrawal from clinical investigation while fully respecting the subjectâ€™s rights.  
â€¢ Ensure that an adequate investigation site team and facilities exist and are maintained 
and documented during the clinical investigation. 
â€¢ Ensure that maintenance and calibration of the equipment relevant for the assessment 
of the clinical investigation is appropriately performed and documented, where 
applic able.  
17.2.1. Delegation of Responsibility  
When specific tasks are delegated by [CONTACT_2413], included but not limited to conducting 
the informed consent process, the investigator is responsible for providing appropriate 
training and adequate supervision of those to whom tasks are delegated. The investigator is 
accountable for regulatory violations resulting from failure to adequately supervise the 
conduct of the clinical study.  
17.3. Institutional Review Board/ Ethics Committee  
Prior to gaining Approval -to-Enroll st atus, the investigational center will provide to the 
sponsor documentation verifying that their IRB/EC is registered or that registration has been 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 48 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 49 of 63 
 
  submitted to the appropriate agency, as applicable according to national/regulatory 
requirements.   
A copy of  the written IRB/EC and/or competent authority approval of the protocol (or 
permission to conduct the study) and Informed Consent Form, must be received by [CONTACT_423565].  Prior approval must also be obtained for 
other  materials related to subject recruitment or which will be provided to the subject.  
Annual IRB/EC approval and renewals will be obtained throughout the duration of the study 
as required by [CONTACT_5737]/country or IRB/EC requirements.  Copi[INVESTIGATOR_5699]â€™s  reports 
and the IRB/EC continuance of approval must be provided to the sponsor.  
17.4. Sponsor Responsibilities  
All information and data sent to [LOCATION_011] Scientific concerning subjects or their participation 
in this study will be considered confidential by [CONTACT_5756] .  Only authorized [LOCATION_011] 
Scientific personnel or a [LOCATION_011] Scientific representative will have access to these 
confidential records.  Authorized regulatory personnel have the right to inspect and copy all 
records pertinent to this study. Study data collected during this study may be used by [CONTACT_423566], publication, and to support future research and/or 
other business purposes.  All data used in the analysis and reporting of this study will be 
without identifiable reference to specific subject name.  
[LOCATION_011] Scientific will keep subjectsâ€™ health information confidential in accordance with all 
applicable laws and regulations.  [LOCATION_011] Scientific may use subjectsâ€™ health information to 
conduct this research,  as well as for additional purposes, such as overseeing and improving 
the performance of its device, new medical research and proposals for developi[INVESTIGATOR_123319], and other business purposes.  Information received during 
the study w ill not be used to market to subjects; subject names will not be placed on any 
mailing lists or sold to anyone for marketing purposes.  
17.5. Insurance  
Where required by [CONTACT_5737]/country regulation, proof and type of insurance coverage, by [CONTACT_423567]. 
18. Monitoring  
Monitoring will be performed during the study to assess continued compliance with the 
protocol and applicable regulations. In addition, the monitor verifies that study records are 
adequately maintained, that  data are reported in a satisfactory manner with respect to 
timeliness, adequacy, and accuracy, and that the investigator continues to have sufficient 
staff and facilities to conduct the study safely and effectively. The investigator/institution 
guarantees direct access to original source documents by [CONTACT_423568], their 
designees, and appropriate regulatory authorities.  
The study may also be subject to a quality assurance audit by [CONTACT_423569], as well as inspection by [CONTACT_4708]. It is important that the 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 49 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 50 of 63 
 
  investigator and relevant study personnel are available during on- site monitoring visits or 
audits and that sufficient time is devoted to the process.  
19. Potential Risks and Benefits 
19.1. General   
The r isks and benefits of performing a transvaginal procedure to treat pelvic organ prolapse 
in the following subjects should be carefully considered due to additional risks associated 
with their conditions:  
â€¢ Women planning future pregnancies  
â€¢ Overweight women (w eight parameters to be determined by [CONTACT_099])  
â€¢ Subjects with blood coagulation disorder  
â€¢ Subjects with a compromised immune system or any other condition that would 
compromise healing  
â€¢ Subjects with renal insufficiency or upper urinary tract obstruction  
19.2. Anticipated Adverse Events  
The following anticipated adverse events (AE) have been reported due to transvaginal 
prolapse kit placement, but are not limited to: 
â€¢ Abscess  
â€¢ Adhesion formation 
â€¢ Allergic reaction, hypersensitivity or other immune reaction  
â€¢ Bleedi ng 
â€¢ Bruising/Hematoma  
â€¢ Constipation/defecatory dysfunction  
â€¢ Dehiscence of vaginal incision (Wound Dehiscence/Surgical Site Wound Irritation)  
â€¢ Dehiscence and/or Necrosis  
â€¢ Detrusor Instability  
â€¢ De Novo Dyspareunia  
â€¢ Edema/Erythema  
â€¢ Exposure  
â€¢ Erosion  
â€¢ Extrusion  
â€¢ Fistula  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 50 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 51 of 63 
 
  â€¢ Granulation tissue formation  
â€¢ Hemorrhage  
â€¢ Incontinence (Urinary)  
â€¢ Infection/Sepsis potentiation  
â€¢ Inflammation  
â€¢ Irritation/Discomfort 
â€¢ Migration of device from desired location  
â€¢ Neuromuscular Events (including groin and leg pain)  
â€¢ Organ perforation  
â€¢ Overactive blad der 
â€¢ Pain 
â€¢ Recurrence  
â€¢ Re-surgery  
â€¢ Retained foreign body (foreign body reaction)  
â€¢ Ureteric Injury  
â€¢ Urinary Retention  
â€¢ Urinary Tract Obstruction (Ureter Obstruction)  
â€¢ Vessel/Nerve Injury/Perforation  
â€¢ Vaginal Discharge (e.g. atypi[INVESTIGATOR_2855])  
â€¢ Vaginal shortening or stenosis, mesh and/or tissue contracture 
â€¢ Sexual Dysfunction  
19.2.1. Mesh Exposure and Erosion Event Classification  
Assessment of mesh exposure and/or erosion will occur at all follow -up visits with pelvic 
examinations performed at 2, 6, 12, 18, 24, and [ADDRESS_534925] -procedure.  Identification of 
mesh exposure and/or erosion will occur by [CONTACT_423570].   
19.3. Risks A ssociated with Participation in the Clinical Stu dy 
There are no additional risks with participation in this clinical study outside of the anticipated 
risks ( see Section 19.2 ) for pelvic organ prolapse as conduct ed according to standard of care 
procedures.   
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 51 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page [ADDRESS_534926]'s physiologic status during research 
procedures and/or follow -ups and by [CONTACT_423571].  
19.5. Anticipated Benefits  
Theoretical benefits of  transvaginally placed mesh for the treatment of pelvic organ prolapse 
may include reduction in POP symptoms.  
19.6. Risk to Benefit Rationale  
The use of transvaginally placed mesh has been shown to reduce recurrent prolapse 
following pelvic floor repair. There have been many randomized controlled trials comparing 
outcomes for pelvic floor repair procedures using mesh grafts to non- mesh repair. Of those 
studies, a reduced incidence of recurrent prolapse in the mesh -procedure group has been 
reported as compared to  non-mesh groups.   
However, the risk of mesh- related complications has been reported and can be linked to risk 
factors including body mass index ( BMI ), concomitant hysterectomy, and physician 
experience.   There is no new literature to indicate there would  be an unsatisfactory risk 
benefit profile for the use of transvaginally placed mesh for the treatment of POP.   
20. Informed Consent 
Subject participation in this clinical study is voluntary.  Informed Consent is required from 
all subjects or their legally au thorized representative. The Investigator is responsible for 
ensuring that Informed Consent is obtained prior to performing any study -required 
procedures and/or testing, or data collection.  
The obtaining and documentation of Informed Consent must be in ac cordance with the 
principles of the Declaration of Helsinki, ISO [ZIP_CODE]:2011 (Clinical investigation of medical 
devices for human subjects -  Good clinical practice) , any applicable national regulations, and 
local Ethics Committee and/or Regulatory authority  body, as applicable.  The ICF must be 
accepted by [CONTACT_423572]  (e.g., CRO), and approved by [CONTACT_16018]â€™s 
IRB/EC, or central IRB, if applicable.  
[LOCATION_011] Scientific will provide a study- specific template of the ICF to investigators 
participating in this study.  The ICF template may be modified to meet the requirements of 
the investigative centerâ€™s IRB/EC.   Any modification requires approval from [LOCATION_011] 
Scientific or its designee  (e.g., CRO) prior to use of the form.  The ICF must be in a language 
understandable to the subject and if needed, BSC will assist the center in obtaining a written 
consent translation.   Translated consent forms must also have IRB/EC approval prior to their 
use.  Privacy language shall be included in the body of the form or as a separate form as 
applicable.   
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 52 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 53 of 63 
 
  The process of obtaining Informed Consent shall:  
â€¢ be conducted by [CONTACT_079] [INVESTIGATOR_123320],  
â€¢ include a description of all aspects of the clinical study that are relevant to the 
subjectâ€™s decision to participate throughout the clinical study, 
â€¢ avoid any coercion of or undue influence of subj ects to participate,  
â€¢ not waive or appear to waive subjectâ€™s legal rights,  
â€¢ use native language that is non- technical and understandable to the subject or his/her 
legal representative,  
â€¢ provide ample time for the subject to consider participation and ask questions if 
necessary,  
â€¢ ensure important new information is provided to new and existing subjects 
throughout the clinical study. 
The ICF shall always be signed and personally dated by [CONTACT_423573].  If a legal representative signs, the subject shall be asked to provide 
informed consent for continued participation as soon as his/her medical condition allows.  
The original signed IC F will be retained by [CONTACT_71657] a copy of the signed and dated 
document and any other written information must be given to the person signing the form.  
Failure to obtain subject consent will be reported by [CONTACT_423574] (e.g., FDA requirement is within 5 working days of learning 
of such an event).  Any violations of the informed consent process must be reported as 
deviations to the sponsor and local regulatory authorities (e.g. IRB/EC), as appropriate.  
If new information becomes available that can significantly affect a subject's future health 
and medical care, that information shall be provided to the affected subject(s) in written form 
via a revised ICF or, in some situations, enrolled subjects may be requested to sign and date 
an addendum to the ICF.  In addition to new significant information during the course of a 
study, other situations may necessitate revision of the ICF, such as if there are amendments 
to the protocol, a change in Principal  Investigator, administrative changes, or following 
annual review by [CONTACT_1201]/EC.  The new version of the ICF must be approved by [CONTACT_1201]/EC. 
[LOCATION_011] Scientific approval is required if changes to the revised ICF are requested by [CONTACT_282085]â€™s IRB/EC.  The IRB/EC will determine the subject population to be re -consented. 
A Screening/Enrollment Log will be maintained to document select information about 
candidates who fail to meet the general or â€œother specificâ€ entry criteria.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 53 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page [ADDRESS_534927] be recorded in the CRF.  
Refer to Section 19 (Potential Risks and Benefits) for the known risks associated with the 
study device(s).  
Definitions o f the adverse events included in the secondary endpoint will match the 
definitions created for the AUGS PFD Registry.  All event definitions will be provided to the 
sites as part of a dictionary in the Manual of Operations.  
When possible, the medical diagnosis should be reported as the Event Term instead of 
individual symptoms.  
If it is unclear whether or not an event fits one of the above categories, or if the event cannot 
be isolated from the device or procedure, it should be submitted as an adverse event  and/or 
device deficiency.  
Underlying diseases are not reported as AEs unless there is an increase in severity or 
frequency during the course of the investigation.  Death should not be recorded as an AE, but 
should only be reflected as an outcome of a spe cific SAE (see Section  21.2 for AE 
definitions).  
21.2. Definitions and Classification  
Adverse event definitions are provided in Table 21.2- 1.  Administrative edits were made to 
combine definitions from ISO [ZIP_CODE]: 2011 (Clinical investigation of medical devices for 
human subjects -  Good clinical practice) and MEDDEV 2.7/3 12/2010. 
 
Table 21.2- 1: Adverse Event Definitions  
Term Definition  
Adverse Event (AE)  
 
Ref: ISO [ZIP_CODE] :2011 
Ref: MEDDEV 2.7/3 12/[ADDRESS_534928] clinical signs (including an abnormal laboratory finding) in 
subjects, users or other persons, whether or not related to the investigational 
medical device.  
NOTE 1:  This inclu des events related to the investigational medical device 
or comparator.  
NOTE 2:  This definition includes events related to the procedures involved 
(any procedure in the clinical investigation plan).  
NOTE 3:  For users or other persons, this definition is restricted to events 
related to the investigational medical device.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 54 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 55 of 63 
 
  Table 21.2- 1: Adverse Event Definitions  
Term Definition  
Serious Adverse Event (SAE)  
 
Ref: ISO [ZIP_CODE]:2011 
Ref: MEDDEV 2.7/3 12/2010 Adverse event that:  
â€¢ Led to death,  
â€¢ Led to serious deterioration in the health of the subject, that either 
resulted in:  
- a life -threatening illness or injury, or  
- a permanent impairment of a body structure or a body function, or  
- in-patient  or prolonged hospi[INVESTIGATOR_272563], 
or 
- medical or surgical intervention to prevent life -threatening il lness 
or injury or permanent impairment to a body structure or a body 
function 
â€¢ Led to fetal distress, fetal death, or a congenital abnormality or birth 
defect.  
NOTE :  Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure 
required by [CONTACT_423575], without serious deterioration in 
health, is not considered a serious adverse event.  
Device Deficiency  
 
Ref: ISO [ZIP_CODE] :2011 
Ref: MEDDEV 2.7/3 12/[ADDRESS_534929] to its 
identity, quality, durability, reliability, safety or performance.  
NOTE :  Device deficiencies include malfunctions, misuse or use er rors, and 
inadequate labeling.  
Abbreviations: EC=Ethics Committee; IRB=Institutional Review Board  
 
21.3. Relationship to Study Device (Mesh Cohort Only)  
The investigator must assess the relationship of the AE to the study device as related or 
unrelated. See criteria in  Table 21.3- 1: 
Table 21.3- 1: Criteria for Assessing Relationship of Study Device to Adverse Event  
Classification  Description  
Unrelated  
(Not Related)  â€¢ The adverse event is determined to be due to a concurrent illness or effect of 
another device/drug and is not related to the investigational product.  
Related  
(Possible, Probable 
or Definite)  â€¢ The adverse event is determined to be potentially related to the investigational 
product, and an alternative etiology is equally or less likely compared to the 
potential relationship to investigational product, or  
â€¢ There is a strong relationship to investigational product, or recurs on re -
challenge, and another etiology is unlikely, or  
â€¢ There is no other reasonable medical explanation for the  event.  
 
21.4. Relationship to Study Delivery Device (Mesh Cohort Only)  
The investigator must assess the relationship of the AE to the study delivery device as related 
or unrelated.  See criteria in  Table 21.4- 1: 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 55 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 56 of 63 
 
  Table 21.4- 1: Criteria for Assessing Relationship of Study Delivery Device to Adverse 
Event  
Classification  Description  
Unrelated  
(Not Related)  â€¢ The adverse event is determined to be due to a concurrent illness or effect of 
another device/drug and is not related to the investigational product.  
Related  
(Possible, Probable 
or Definite)  â€¢ The adverse event is determined to be potentially related to the investigational 
product, and an alternative etiology is equally or less likely compared to the 
potential relationship to investigational product, or  
â€¢ There is a strong relationship to investigational product, or recurs on re -
challenge, and an other etiology is unlikely, or  
â€¢ There is no other reasonable medical explanation for the event.  
 
21.5. Relationship to Study Procedure  
The investigator must assess the relationship of the AE to the study procedure as unrelated, 
possibly related, probably related, or definitely related. See criteria in Table 21.5- 1. 
Table 21.5- 1: Criteria for Assessing Relationship to Study Procedure 
Classification  Description  
Unrelated  
(Not Related)  â€¢ No evidence that the timing of the adverse event has a relationship to the study 
procedure performed.  
Possibly Related  â€¢ The adverse event has a timely relationship to the study procedure performed.  
However, a potential alternative etiology may be responsible for the adverse 
event.  
Probably Related  â€¢ The adverse event has a timely relationship to the study procedure performed and 
the causative relationship can be clearly established. No potential alternative 
etiology is apparent.  
Definitely Related  â€¢ The adverse event has a timely relationship to the study procedure performed and 
the causative relationship can be clearly established. No potential alternative 
etiology is apparent.  
â€¢ There is no other reasonable medical explanation for the event.  
 
21.6. Relationship to Pelvic Floor  
The investigator must assess the relationship of the AE to the pelvic floor as unrelated or 
related. See criteria in Table 21.6- 1. 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 56 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 57 of 63 
 
  Table 21.6- 1: Criteria for Assessing Relationship to Pelvic Floor  
Classification  Description  
Unrelated  â€¢ No evidence that the adverse event has a relationship to the pelvic floor and 
supporting tissues . 
Related  
 â€¢ The adverse event is determined to be potentially related to the pelvic floor and 
supporting tissues including but not limited to lacerations, avulsions, tears, pelvic 
organ prolapse (cystocele, rectocele, enterocele, uterine, rectal), urinary 
incontinence (stress, urge), urinary voiding dysfunction (retention, obstructed 
voiding, incomplete emptying), fecal incontinence (urgency, irritable bowel 
syndrome), defecatory dysfunction (constipation, obstipation, stool trappi[INVESTIGATOR_007], 
IBS), pain (dyspareunia, pelvic, perineal), and infecti on (bladder, urinary tract, 
vaginal).  
â€¢ There is a strong relationship to the pelvic floor and supporting tissues, and 
another etiology is unlikely, or  
â€¢ There is no other reasonable medical explanation for the event.  
 
21.7. Investigator Reporting Requirements  
The communication requirements for reporting to BSC are as shown in Table 21.7- 1. 
Table 21.7- 1: Investigator Reporting Requirements  
Event Classification  Communication Method  Communication Timeline  
Serious Adverse Events related to the 
study device, procedure and/or pelvic 
floor  or events resulting in death 
regardless of relationship to the 
device, procedure or pelvic floor.  
 Complete AE CRF page with 
all available new and updated 
information.  
 â€¢ Within [ADDRESS_534930] 
becoming aware of the event 
or as per local/regional 
regulations.  
â€¢ Reporting required through the 
end of the study.  
If requested by [CONTACT_2728] , 
provide all relevant source 
documentation (unidentified) 
for the reported event.  â€¢ When documentation is 
available  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 57 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 58 of 63 
 
  Table 21.7- 1: Investigator Reporting Requirements  
Event Classification  Communication Method  Communication Timeline  
Adverse Events related to the study 
device and/or procedure.  
Events assessed for reporting shall 
include but are not  limited to:  
â€¢ Pelvic pain  
â€¢ Infection (by [CONTACT_24975])  
â€¢ De novo dyspareunia  
â€¢ Vaginal shortening  
â€¢ Vaginal scarring  
â€¢ De novo vaginal bleeding  
â€¢ Atypi[INVESTIGATOR_67260]  
â€¢ Fistula formation  
â€¢ De novo voiding dysfunction 
(including de novo 
incontinence)  
â€¢ Neuromuscular problems 
(including groin and leg pain)  
â€¢ Revision/re -surgery  
â€¢ Recurrent prolapse  
â€¢ Mesh exposure  
â€¢ Mesh erosion  Complete the AE CRF page, 
which contains such 
information as onset date of 
the AE, treatment provided if 
any, resolution, assessment of 
seriousness, and relati onship to 
study device.  â€¢ In a timely manner (e.g., 
recommended within [ADDRESS_534931] 
becoming aware of the event) . 
â€¢ Reporting required through 
end of subject participation . 
Adverse Events related to the pelvic 
floor.  
Events assessed for reporting shall 
include but are not limited to:  
â€¢ Urinary tract infections  
â€¢ Pelvic organ prolapse  
â€¢ Urinary incontinence  
â€¢ Fecal incontinence  
â€¢ Pelvic Pain  Complete the AE CRF page, 
which contains such 
information as onset date of 
the AE, treatment provided if 
any, resolution, assessment of 
seriousness, and relationship to 
study device . â€¢ In a timely manner (e.g., 
recommended within [ADDRESS_534932] 
becoming aware of the event).  
â€¢ Reporting required through 
end of subject participation.  
Device Deficiencies (including but 
not limited to failures, malfunctions, 
and product nonconformities)  
NOTE :  Any Investigational Device 
Deficiency that might have led to a 
serious adverse event if a) suitable 
action had not been taken or b) 
intervention had not been made or c) 
if circumstances had been less 
fortunate is considered a reportable 
event.  Complete CRF  with all 
available new and updated 
information . â€¢ Within [ADDRESS_534933] 
becoming aware of the event . 
â€¢ Reporting required through the 
end of the study.  
Abbreviations: AE=adverse event; CRF=case report form  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 58 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 59 of 63 
 
  21.8. [LOCATION_011] Scientific Device Deficiencies 
All device deficiencies (including but not limited to complications, malfunctions, use errors, 
product nonconformities, and labeling errors) will be documented and reported to [LOCATION_011] 
Scientific .  If possible, the device(s) should be returned to BSC for analysis. Instructions for 
returning the device(s) will be provided.  If it is not possible to return the device, the 
investigator should document why the device was not returned and the final disposition of the 
device.  Device failures and malfunctions should also be documented in the subjectâ€™s medical 
record.  
Device deficiencies (including but not limited to failures, malfunctions, and product 
nonconformities) are not to be reported as adverse events.  However, if there is an adverse 
event that results from a device failure or malfunction, that specific event w ould be recorded 
on the appropriate CRF. 
Any Device Deficiency that might have led to a serious adverse event if a) suitable action 
had not been taken or b) intervention had not been made or c) if circumstances had been less 
fortunate is considered a repor table event.  
21.9. Reporting to Regulatory Authorities / IRBs / ECs / Investigators  
[LOCATION_011] Scientific is responsible for reporting adverse event information to all participating 
investigators and regulatory authorities, as applicable.  
The Principal Investigator [INVESTIGATOR_5703]/EC, and regulatory 
authorities of an SAE as required by [CONTACT_5737]/regional regulations. 
22. Committees 
22.1. Safety Monitoring Process  
To promote early detection of safety issues, an internal Safety Monitoring Team will provide 
evaluations of safety events.  Success of this program requires dynamic collection of 
unmonitored data as soon as the event is reported.  This is expedited through [LOCATION_011] 
Scientificâ€™s Safety Office, which is responsible for coordinating the collection of infor mation 
for the subject dossier from the centers.  During regularly scheduled monitoring visits, 
clinical research monitors will support the dynamic reporting process through their review of 
source document information.  
23. Suspension or Termination  
23.1. Premature T ermination of the Study  
[LOCATION_011] Scientific reserves the right to terminate the study at any stage but intends to exercise 
this right only for valid scientific or administrative reasons and reasons related to protection 
of subjects.  Investigators, associated IRBs/ECs, and regulatory authorities, as applicable, 
will be notified in writing in the event of study termination.  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 59 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 60 of 63 
 
  23.1.1. Criteria for Premature Termination of the Study  
Possible reasons for premature study termination include, but are not limited to, the 
following. 
â€¢ The occurrence of safety events that present a significant or unreasonable risk to 
subjects enrolled in the study.  
â€¢ An enrollment rate far below expectation that prejudices the conclusion of the study.  
â€¢ A decision on the part of [LOCATION_011] Scientific to suspend or discontinue development of 
the device.  
23.2. Termination of Study Participation by [CONTACT_5717]/ EC 
Approval  
Any investigator, or IRB/ EC in the Uphold LITE Study may discontinue participation in the 
study or withdrawal approval of the study, respectively, with suitable written notice to 
[LOCATION_011] Scientific.  Investigators, associated IRBs/ECs, and regulatory authorities, as 
applicable, will be notified in writing in the event of these occurrences.  
23.3. Requirements for Documentation and Subject Follow -up 
In the event of premature study termination a written statement as to why the premature 
termination has occurred will be provided to all participating centers by [CONTACT_5756]. 
The IRB/EC and regulatory authorities, as applicable, will be notified.  Detailed information 
on how enrolled subjects will be managed thereafter will be provided.  
In the event an IRB or EC terminates participation in the study, participating investigators, 
associated IRBs/ECs, and regulatory authorities, a s applicable, will be notified in writing. 
Detailed information on how enrolled subjects will be managed thereafter will be provided 
by [CONTACT_5756].  
In the event an investigator terminates participation in the study, study responsibility will be 
transferred to a co -investigator, if possible.  In the event there are no opportunities to transfer 
investigator responsibility; detailed information on how enrolled subjects will be managed 
thereafter will be provided by [CONTACT_5756].  
23.4. Criteria for Suspen ding/Terminating a Study Center  
[LOCATION_011] Scientific reserves the right to stop the inclusion of subjects at a study center at any 
time after the study initiation visit if no subjects have been enrolled for a period beyond 12 
months after center initiation, or if the center has multiple or severe protocol 
violations/noncompliance without justification and/or fails to follow remedial actions.  
In the event of termination of investigator participation, all testing equipment, as applicable, 
will be returned to Bo ston Scientific unless this action would jeopardize the rights, safety or 
well-being of the subjects.  The IRB/EC and regulatory authorities, as applicable, should be 
notified.  All subjects enrolled in the study at the center will continue to be followed per 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 60 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page [ADDRESS_534934] Research, [LOCATION_011] Scientific will submit 
study results for publication (regardless of study outcome) following the conclusion or 
termination of the study. [LOCATION_011] Scientific adheres to the Contributorship Criteria set forth in 
the Uniform Requirements of the International Committee of Medical Journal Editors 
(ICMJE; http://www.icmje.org).  In order to ensure the public disclosure of study results in a 
timely manner, while maintaining an unbiased presentation of study outcomes, BSC 
personnel may assist au thors and investigators in publication preparation provided the 
following guidelines are followed. 
â€¢ All authorship and contributorship requirements as described above must be 
followed. 
â€¢ [LOCATION_011] Scientific involvement in the publication preparation and the Bos ton 
Scientific Publication Policy should be discussed with the Coordinating Principal 
Investigator(s) and/or Executive/Steering Committee at the onset of the project.  
â€¢ The First and Senior authors are the primary drivers of decisions regarding 
publication c ontent, review, approval, and submission.  
  
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 61 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page 62 of 63 
 
  25. References  
1 Clark, A.L., Gregory, T., Smith, V.J., and Edwards, R. Epi[INVESTIGATOR_423528]. American Journal of Obstetrics a nd Gynecology 2003; 
189, 1261- [ADDRESS_534935] P, Guilbaud O, Eglin G; French Ugytex Study Group. Prolapse 
repair by [CONTACT_423576] a new protected low -weight polypropylene mesh: 1- year functional and anatomical 
outcome in a prospective multicentre study. Int Urogynecol J Pelvic Floor Dysfunct. 2007 Mar;18(3):251- 6 
3 Hiltunen R, Nieminen K, Takala T, Heiskanen E, Merikari M, Niemi K, Heinonen PK. Low -weight 
polypropylene mesh for anterior vaginal wall prolapse: a ran domized controlled trial. Obstet Gynecol 
2007;110:455 -62. 
4 Iglesia CB, Sokol AI, Sokol ER, Kudish BI, Gutman RE, Peterson JL, Shott S. Vaginal mesh for prolapse: a 
randomized controlled trial. Obstet Gynecol 2010;116:293 -303. 
5 McIntyre M. Goudelocke C. R ovner E.S. An update on surgery for pelvic organ prolapse. Current Opi[INVESTIGATOR_423529]. (2010) 20:6, (490- 494).  
6 Milani R, Salvatore S, Soligo M, Pi[INVESTIGATOR_423530] P, Meschia M, Cortese M. Functional and anatomical outcome of 
anterior and posterior vaginal prolaps e repair with prolene mesh. BJOG. 2005 Jan;112(1):107- [ADDRESS_534936]. 2010 May;21(5):[ADDRESS_534937] IE, McCreery R, Brubaker L, Connolly A, Cundiff G, Weber AM, Zyczynski H; Pelvic Floor 
Disorders Network.. Abdominal sacrocolpopexy: a comprehens ive review. Obstet Gynecol 2004; 104:805- 23. 
9 Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epi[INVESTIGATOR_423531]. Obstet Gynecol 1997; 89:501Â¬6  
10 Takahashi S, Obinata D, Sakuma T, Nag ane Y, Sato K, Mochida J, Ichinose T, Yamaguchi K. Tension -free 
vaginal mesh procedure for pelvic organ prolapse: a single -center experience of 310 cases with 1 -year follow 
up. Int J Urol. 2010 Apr;17(4):353- [ADDRESS_534938]  LA. Anterior colporrhaphy: A randomized trial of three 
surgical techniques. Am J Obstet Gynecol 2001;185:1299 -1306.  
12 Altman D, VÃ¤yrynen T, Engh ME, Axelsen S, Falconer C; Nordic Transvaginal Mesh Group. Anterior 
Colporrhaphy versus Transvaginal Mesh for Pelvic -Organ Prolapse. NEJM 2011 May 12: 364(19):1826 -1836.  
13 Nguyen JN, Burchette RJ. Outcome After Anterior Vaginal  Prolapse Repair: A Randomized Controlled Trial. 
Ob Gyn 2008 Apr;111(4):891 -898. 
14 Nieminen K, Hiltunen R, Takala T, Heiskanen E, Merikari M, Niemi K, Heinonen PK. Outcomes after 
anterior vaginal wall repair with mesh: a randomized, controlled trial with a 3 year follow -up. AJOG 2010 
Sept;235e1 -235e8.  
15 Sivaslioglu AA, Unlubilgin E, Dolen K. A randomized comparison of polypropylene mesh surgery with site -
specific surgery in the treatment of cystocoele. Int Ugoyn J 2008;19:467- 471. 
16 Carey M1, Higgs P, Go h J, Lim J, Leong A, Krause H, Cornish A. Vaginal repair with mesh versus 
colporrhaphy for prolapse: a randomized controlled trial. BJOG 2009;116:1380- 1386.  
[ADDRESS_534939] HA, Vierhout ME. Trocar- Guided Mesh Compared With 
Conventional Vaginal Repair in Recurrent Prolapse: A Randomized Controlled Trial. Ob Gyn 2011 Feb;117(2) 
Part 1:242 -250. 
18 Colombo M, Milani R. Sacrospi[INVESTIGATOR_423532]. Am J Obstet Gynecol 1998;179:13- 20. 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 62 of 63 
PS130044  Protocol U8090 â€“  Uphold LITE, 90886984, Rev/Ver AI   
Confidential  Page [ADDRESS_534940], Carey MP, Cornish A, Schluter PJ. Abdominal sacral colpopexy or 
vaginal sacrospi[INVESTIGATOR_423533]: a prospective randomized study. Am J Obstet 
Gynecol 2004;190:20 -6. 
20 Shull BL, Capen CV, Riggs MW, Kuehl TJ. Preoperative and postoperative analysis of site -specific pelvic 
support defects in 81 women treated with sacrospi[INVESTIGATOR_423534]. Am J 
Obstet Gynecol 192;166:1764- 8. 
21 Benson JT, Lucente V, McClellan E. Vaginal versus abdominal reconstructive surgery for the treatment of 
pelvic support defects: A prospective randomized study with long -term outcome evaluation. Am J Obstet 
Gynecol 1996:175:1418 -21. 
22 Diwadkar  GB, Barber MD, Feiner B, Maher C, Jelovsek JE. Complication and Reoperation Rates After 
Api[INVESTIGATOR_423535]. Ob Gyn 2009:113(2):367- 373. 
23 Abed H, Rahn DD, Lowenstein L, Balk EM, Clemons JL, Rogers RG.  Incidence and management of gra ft 
erosion, wound granulation, and dyspareunia following vaginal prolapse repair with graft materials:  as 
systematic review.  Int Urogynecol J (2011) 22:789 -798. 
24 Vollebregt A, Fischer K, Gietelink D, and Van Der Vaart CH. BJOG: An International Journal  of Obstetrics 
and Gynaecology 2011 118:12 (1518- 1527).  
 
[LOCATION_011] Scientific  Confidential . Unauthorized  use is prohibited .
Released
90886984  AI.2
Uphold LITE Protocol
Page 63 of 63 